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in Oligodendrocyte Progenitor Cells 
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Abstract 
 
Oligodendrocyte progenitor cells (OPCs) are precursor cells that give rise to 
oligodendrocytes. Oligodendrocytes are the cells that form myelin, an arrangement of 
membrane sheaths enwrapping axons necessary for the fast transmission of electrical 
impulses in the central nervous system (CNS). OPCs generate oligodendrocytes both 
during development and adulthood and also after the myelin damage caused by injury or 
demyelinating disease. 
 
Generation of oligodendrocytes from OPCs is in part regulated by growth factors. The 
major survival factor and mitogen for OPCs is platelet derived growth factor (PDGF). 
PDGF and its receptor, PDGF receptor A (PDGFRA), are critical regulators of OPC 
proliferation and their differentiation into myelinating oligodendrocytes. PDGFRA gain-of-
function can lead to excessive proliferation and is associated with a number of cancers, 
including glioma in the CNS. In terms of the role of PDGFRA in OPC differentiation, 
there is evidence that suggests that signaling through PDGFRA needs to be inhibited in 
order for OPC differentiation to occur. 
 
	  Jelena Medved – University of Connecticut, 2014 
 
The goal of this study is to identify small molecule compounds that inhibit Pdgfra 
transcription in oligodendrocyte precursor cells. We hypothesized that inhibition of 
Pdgfra transcription by small molecule compounds would result in inhibition of OPC 
proliferation and stimulation of their differentiation into mature oligodendrocytes. 
Identification of such compounds may provide a novel direction in drug design for 
demyelinating disorders or specific types of cancers caused by aberrant Pdgfra 
expression. 
 
We identified a group of compounds that downregulated Pdgfra transcription in Oli-neu 
cells, a cell line that represents mouse oligodendrocyte precursor cells, and that inhibited 
proliferation of PDGFRA-expressing Oli-neu cells and primary mouse OPCs but did not 
inhibit proliferation of primary mouse astrocytes and HEK 293 cells, that do not express 
PDGFRA, or glioblastoma-derived cell lines. However, these compounds did not 
promote differentiation of primary mouse OPCs. 
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Introduction 
 
Oligodendrocyte progenitor cells (OPCs, NG2 cells, polydendrocytes) represent a 
population of cells in the central nervous system (CNS) that is distinct from all other cell 
types (reviewed by Nishiyama, et al, 2009). OPCs are uniformly distributed throughout 
the gray and white matter and persist as the largest population of cycling cells in the 
adult mammalian CNS (Dawson et al, 2003). They are the major source of 
oligodendrocytes (Zhu et al, 2008), cells that generate myelin sheaths necessary for 
rapid conduction of electrical impulses in the CNS.  
 
Generation of oligodendrocytes occurs both during development and adulthood in 
healthy rodent brain. However, OPCs can give rise to oligodendrocytes in pathological 
conditions as well. Upon myelin damage, OPCs proliferate and differentiate to 
compensate for myelin loss (reviewed by Miron et al, 2011). In fact, acute myelin lesions 
are efficiently repaired (Zawadzka et al, 2010). Chronic lesions however, such as those 
found in multiple sclerosis (MS) and its rodent models, are not remyelinated efficiently 
(Tripathi et al, 2010). It is not determined why OPCs are unable to repair myelin damage 
under these conditions, but one possibility is that OPC are inhibited from differentiation 
into myelinating oligodendrocytes (Kuhlman et al, 2008).  
 
OPCs are commonly identified by the expression of platelet derived growth factor 
(PDGF) receptor A (PDGFRA). Signaling through PDGFRA is the key mechanism in 
regulation of OPC proliferation and differentiation. A large body of evidence indicates 
that PDGF is the major mitogen for OPCs (Noble et al, 1988; Richardson et al, 1988; 
Barres et al, 1992; Calver et al, 1998; Fruttiger et al, 1999; van Heyningen et al, 2001). 
PDGF presence is necessary for OPC proliferation in vitro and its withdrawal causes 
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rapid differentiation of OPCs. Studies have suggested the default pathway that OPCs 
undertake is differentiation. This pathway is normally inhibited by PDGFRA signaling in 
progenitor cells and signaling through PDGFRA needs to be repressed in order for 
OPCs to differentiate. Since PDGFRA is present in OPCs, but gets downregulated as 
OPCs differentiate, it is likely that PDGFRA and its downregulation are critical factors 
that control oligodendrocyte differentiation and that PDGFRA has to be downregulated in 
order for OPCs to differentiate (McKinnon et al, 2005; Zhu et al, 2014). However, 
molecular mechanisms that lead to PDGFRA repression and therefore trigger 
differentiation remain to be defined.  
 
The goal of this study is to identify small molecule compounds that downregulate 
PDGFRA transcription. This may contribute in understanding the mechanism of 
PDGFRA expression and provide a novel direction in drug design for demyelinating 
disorders or specific types of cancers caused by aberrant PDGFRA expression. 
 
To address this goal, we performed experiments outlined in the Specific Aims below. 
 
Aim 1: Identify lead compounds that downregulate the transcription of PDGFRA. 
Aim 2: Examine structure activity relationship. 
Aim 3: Determine whether the compounds promote OPC differentiation. 
Aim 4: Determine whether the compounds inhibit OPC proliferation. 
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Chapter 1 - Background	  
 
Brief history of glia 
 
Early in the 19th century, Theodor Schwann recognized a cell as the fundamental unit of 
all living organisms. It was not until well into the 20th century, however, that 
neuroscientists agreed that nervous tissue, like all other organs, is made up of these 
fundamental units. The major reason was that the first generation of neurobiologists in 
the 19th century had difficulty resolving the unitary nature of nerve cells with the 
microscopes and cell staining techniques that were then available. As a result, some 
biologists of that era concluded that each nerve cell was connected to its neighbors 
forming a continuous network, or reticulum. The “reticular theory”	   of nerve cell 
communication, led by Italian neuropathologist Camillo Golgi, was eventually replaced 
with	   “neuron doctrine”	  by Spanish neuroanatomist Santiago Ramon y Cajal and British 
physiologist Charles Sherrington. The histological studies of Cajal, Golgi and many 
successors led to the further consensus that the cells of the nervous system can be 
divided into two broad categories: neurons and glia.  
 
For the past 160 years, cells in the nervous system have been divided into neurons and 
glia (reviewed by Kettenmann and Verkhratsky, 2008). An idea on the brain connective 
tissue, the “nervenkitt”, nerve cement or neuroglia was proposed by Rudolf Virchow in 
the mid 19th century. The term neuroglia and the concept behind them spread around 
the world. Soon after, many different forms of glial cells were described by Deiters, 
Henle, Retzius, Golgi and others (Deiters, 1865; Henle and Merkel, 1869; Retzius, 1894; 
Golgi, 1903). In the late 19th century, Michael von Lenhossek proposed the term 
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“astrocyte” (von Lenhossek, 1893) and slightly later, Kolliker (Kolliker, 1889) and 
Anderiezen (Andriezen, 1893) divided those into fibrous and protoplasmic astoryctes. 
Pio del Rio-Hortega recognized oligodendrocytes and microglia in the early 20th century 
and added them to the growing list of glial subtypes (del Rio-Hortega, 1919; 1921; 
1932). It was not until mid 20th century that myelin, the term also introduced by Virchow, 
was recognized to be part of the Schwann cell (Geren, 1954).  
 
OPCs as the fourth population of glia 
 
The initial division of glia into three types, astrocytes, oligodendrocytes and microglia, 
accomplished in the mid 19th century, has recently been challenged. An entirely new 
class of glial cells, oligodendrocyte progenitor cells (OPCs), also known as 
polydendrocytes (Nishiyama et al, 2007), has been characterized and proposed as the 
4th major population of glia (Nishiyama et al, 2009).  
 
OPCs were discovered in the late 20th century and were thought to be precursor cells 
that most commonly generate oligodendrocytes, but can also generate astrocytes in 
some cases (Raff et al, 1989; Zhu et al, 2008; Zhu et al, 2011) and even neurons 
(Kondo and Raff, 2000; Rivers et al, 2008; Guo et al, 2009; Guo et al, 2010). However, 
OPCs are not solely progenitor cells. They can be considered a distinct type of glia for 
several reasons. First, they are uniformly distributed population of cells in gray and white 
matter of healthy adult rodent brain that persists into adulthood as the major pool of 
cycling cells and is as abundant as other cell types (Dawson et al, 2003). Second, the 
pattern of expressed markers distinguishes these cells from all the others. In addition, 
these is increasing evidence that suggests a population of OPCs persists in adult brain 
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and does not differentiate into oligodendrocytes, so it is likely that OPCs have a far more 
complex role in nervous system physiology that we are not yet aware of. 
 
OPC development and fate choices 
 
OPCs originate from discrete parts of the ventricular zone (VZ) but the region of VZ that 
will give rise to OPCs is different at different time points during development and 
temporarily progresses from the ventral towards the dorsal part of the VZ (Warf et al, 
1991; Kessaris et al, 2006; reviewed by Richardson et al, 2006). Once committed to 
oligodendrocyte lineage, OPCs migrate away from the VZ through the developing CNS 
and into what will become the white matter of the CNS (Reynolds et al, 1988; Levine et 
al, 1988). OPCs continue to divide after they leave the VZ. Once they settle at their final 
destinations, OPCs will exit the cell cycle, express myelin genes and mature to fully 
differentiated oligodendrocytes (reviewed by Baumann and Pharm-Dinh, 2001). 
However, not all OPCs will differentiate. A population of OPCs persists in the rodent 
cortex throughout adulthood (Reynolds et al, 1997; Dawson et al, 2003).  
 
When originally discovered, OPCs were considered bipotent glial precursors and were 
named O-2A progenitor cells because in vitro, they were capable of generating both 
oligodendrocytes and type-2 astrocytes (Raff et al, 1983). When cultured with PDGF 
producing type-1 astrocytes (Richardson et al, 1988) or simply PDGF (Noble et al, 
1988), OPCs divide and exhibit features of progenitor cells over a period of several 
weeks (Noble and Murray, 1984; Raff et al, 1985; Dubois-Daicq, 1987), perhaps even 
indefinitely (Barres et al, 1994). If type-1 astrocytes are removed (Abney et al, 1981; Raff 
et al, 1985; Dubois-Dalcq et al, 1986) or PDGF is withdrawn (Noble and Murray, 1984; 
Temple and Raff, 1985; Behar et al, 1988), OPCs rapidly differentiate into 
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oligodendrocytes. OPCs also differentiate into oligodendrocytes if thyroid hormone has 
been added to the culture medium (Barres et al, 1994). To the contrary, addition of fetal 
bovine serum (FBS) triggers OPCs to obtain features of type-2 astrocytes (Raff et al, 
1983; Raff et al, 1989). Some reports suggested that, depending on culture conditions, 
OPCs could differentiate into neurons as well (Kondo and Raff, 2000).  
 
OPC fate choice in vivo has been controversial until the generation of transgenic mice 
that express cre recombinase under the control of OPC-specific genes. With this 
approach, it has been confirmed that that these cells are precursor cells that most 
commonly generate oligodendrocytes. However, their multipotency is limited in vivo. It 
was indeed true that OPCs can generate astrocytes in healthy rodent tissue as well, but 
this fate choice occurs only during prenatal development and only in specific regions of 
the forebrain (Zhu et al, 2008; Zhu et al, 2011). Although few studies showed that OPCs 
generate a small number of neurons in vivo (Rivers et al, 2008; Guo et al, 2009; Guo et 
al, 2010), the question of their neuronal fate is still debatable. 
 
Markers that identify stages of OPC development 
 
Starting from neural stem cell up to fully differentiated myelinating oligodendrocyte, 
oligodendrocyte lineage cell goes through several stages. Each stage can be identified 
by the expression of specific antigenic markers. Although these markers are commonly 
used to identify different stages of oligodendrocyte development by immunocyto- and 
histochemistry, it needs to be kept in mind that they are not solely markers, but also 
have important roles in the development of oligodendrocyte lineage cells. Transition from 
one stage to the next does not usually involve the loss of only one marker and 
acquisition of another one. So it is a unique pattern, rather than a single component, that 
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divides the path of oligodendrocyte differentiation into distinct phenotypic stages (Figure 
1). 
 
Oligodendrocyte transcription factor 1 (Olig1) and 2 (Olig2) and several members of the 
Sry-related HMG box (Sox) family are the earliest markers of oligodendrocyte lineage 
(Lu et al, 2000; Zhuo et al, 2000; Takebayashi et al, 2000; Stolt et al, 2002; Britsch et al, 
2001; Kuhlbrod et al, 1998). Olig2 is also expressed by motor neuron precursors and is 
critical for generation of both OPCs and motor neurons (Lu et al., 2002; Takebayashi et 
al., 2002). Contrary to that, Olig1 is not essential for OPC production. Although its 
transcription starts less than a day after that of Olig2 (Zhou et al, 2000), it has been 
shown to play roles in oligodendrocyte development postnatally and is important for 
oligodendrocyte maturation and myelination in the CNS (Lu et al, 2002; Xin et al, 2005). 
Olig2 is a likely candidate that induces expression of Sox10 (Kuhlbrodt et al. 1998; Zhou 
et al, 2000; Stolt et al, 2002), which is likely the first transcription factor that marks cells 
committed to oligodendrocyte lineage (Kuhlbrod et al, 1998) and is critical for their 
differentiation into myelinating oligodendrocytes (Stolt et al, 2002). The expression of 
Olig1, Olig2 and Sox10 will persist throughout all stages of oligodendrocyte 
differentiation. 
 
The most widely used markers for OPCs are PDGFRA and chondroitin sulphate 
proteoglycan 4 (CSPG4, NG2). Pdgfra transcript first appears at least one day upon 
initial specification of OPCs and is most likely induced by Sox family of transcription 
factors (Lu et al, 2000; Zhou et al, 2000; Tekki-Kessaris et al, 2001; Finzsch et al, 2008). 
NG2 expression follows that of PDGFRA, on cells that have exited the VZ (Nishyama et 
al, 1996; Zhu and Nishiyama; 2013). NG2 and PDGFRA will be coexpressed by OPCs 
as they migrate away from the VZ, but will be coordinately downregulated as the 
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progenitors differentiate (Nishiyama et al, 1996; Keirstead et al, 1998; Dawson et al, 
2003). 
 
As OPCs differentiate, they start expressing lipid antigens recognized by monoclonal 
antibodies O4 and O1. A population of O4 positive cells coexpresses NG2 and PDGFRA 
(Reynolds and Hardy, 1997). As OPCs transition to the stage of early (immature, 
premyelinating) oligodendrocyte, they lose the expression of NG2 and PDGFRA and the 
ability to proliferate and acquire the expression of galactocerebroside (GC, GalC) 
recognized by O1 antibody (Gard et al, 1990).  
 
Myelin basic protein (MBP), myelin associated glycoprotein (MAG), myelin 
oligodendrocyte glycoprotein (MOG) and myelin proteolipid protein (PLP) are classical 
markers expressed by mature oligodendrocytes and myelinated axons. MBP, MAG and 
PLP appear sequentially both in vitro (Dubois-Dalcq et al, 1986) and in vivo (Monge et 
al, 1986). 	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Figure 1. Markers that identify different stages of oligodendrocyte 
differentiation. Although not expressed exclusively by OPCs, but also by motoneuron 
precursors, Olig2 is the first marker of oligodendrocyte lineage cells. It is followed by 
Olig1 and Sox10, which expression will persist throughout an entire lineage. PDGFRA 
and NG2 are the most commonly used markers for OPCs that are downregulated as 
OPCs mature. As OPCs mature, they acquire the expression of O4 antigens, which is 
followed by O1 antigens and CNP. Late (mature) oligodendrocytes are identified by the 
expression of MBP, MAG, PLP and MOG, which appear in sequential manner.	  
 
11	  
Role of OPCs in remyelination	  
 
In response to a variety of insults to the CNS, OPCs become activated and undergo 
morphological changes, such as hypertrophy of the cell body and processes as well as 
increase in proliferation (Levine et al, 1994, Keirstead et al, 1998; Nishiyama et al, 1997; 
Di Bello et al., 1999; Levine and Reynolds, 1999). If the insult is directed towards 
oligodendrocytes resulting in their damage and death, OPCs will repopulate the 
oligodendrocyte-deprived areas and differentiate into oligodendrocytes in order to 
compensate for their loss (Tripathi et al, 2010; Zawadzka et al, 2010).  
 
MS is an autoimmune disease of the CNS, characterized by inflammation, demyelination 
and astogliosis (Charcot, 1868; Frohman et al, 2006). Although axonal degeneration 
occurs in MS (Ferguson et al, 1997), oligodendrocytes and myelin are the principal 
targets of the inflammatory process. In the early stages of the disease, acute 
demyelination is associated with remyelination (Gledhill, 1973). However, long-standing, 
chronic lesions are not remyelinated efficiently (Keirstead and Blakemore, 1999). 
Although the source of remyelinating oligodendrocytes in MS remains unclear, studies 
have revealed the presence of OPCs in and around demyelinating lesions of MS (Wilson 
et al, 2006). Adult OPCs are shown to be the cells that generate oligodendrocytes 
following experimental demyelination in rodents in both acute (Zawadzka et al, 2010) 
and chronic (Tripathi et al, 2010) models of demyelination. In fact, acute demyelinating 
lesions are efficiently repaired (Zawadzka et al, 2010). Studies have implied that 
remyelination is not limited by an absence of OPCs in demyelinating lesions, but may be 
the result of OPC inability to differentiate into myelinating oligodendrocytes (Kuhlman et 
al, 2008). Current MS treatments focus on the immunomodulation of the inflammatory 
component of the disease and little progress has been made toward therapies that 
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promote the regenerative process of remyelination. However, this would be a highly 
effective complement to the immunomodulatory drugs. 
 
Regulation of OPC proliferation and differentiation by PDGF 
 
Oligodendrocyte differentiation in culture is regulated by various growth factors, such as 
platelet derived growth factor (PDGF), fibroblast growth factor (FGF), ciliary neutrophic 
factor (CNTF) CNTF and triiodothyronine (T3) (Barres et al, 1994; Noble et al, 1988; Raff 
et al, 1985; Raff et al, 1988). However, a large body of evidence shows that PDGF is the 
key regulator of OPC proliferation and differentiation both in vitro and during 
development (van Heyningen et al, 2001). Numerous studies have confirmed that PDGF 
is a major mitogen for OPCs (Noble and Murray, 1984; Noble et al, 1988; Richardson et 
al, 1988; Raff et al, 1988; Pringle et al, 1989, McKinnon et al, 1990; Raff et al, 1988; 
Pringle et al, 1989; Richardson et al, 1988; Noble et al, 1988). PDGF promotes survival 
(Barres et al, 1992), division and motility (Noble, 1988) of OPCs. At the same time, 
PDGF signaling has been shown to inhibit OPC differentiation in vitro and its withdrawal 
from the culture medium is sufficient to trigger OPC differentiation (Raff et al, 1985; Raff 
et al, 1988; van Heyningen et al, 2001). Early studies on the effect of PDGF on OPCs 
proposed that PDGF drives an “internal clock”	   that counts cell divisions and regulates 
the timing of OL development in culture (Raff et al, 1985; Raff et al, 1988). However 
some of the later studies suggested that in the presence of PDGF, OPCs can divide 
indefinitely (Barres et al, 1994). Although it is evident that PDGF has an important role in 
regulation of OPC differentiation, its role is more complex than a simple on/off switch 
and is still incompletely understood.  
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In vivo, PDGF is most likely produced by astrocytes (Raff et al, 1985; Richardson et al, 
1988) and neurons (Yeh et al, 1991). Its presence in the rodent CNS throughout 
gliogenesis (Richardson et al, 1988; Pringle et al, 1989) suggests its role in the control of 
OPC differentiation and myelination in vivo. Its importance is further supported by the 
evidence that aberrant PDGF expression in vivo can altar OPC survival, proliferation and 
timing of their differentiation (Calver et al, 1998; Fruttiger et al, 1999).  
 
A family of PDGFs includes 4 isoforms, named PDGFA, B, C and D. All isoforms are 
secreted as disulfide-linked bivalent ligands that can form both homomers and 
heteromers. PDGFs exert their effect through their receptors, PDGFRA and B. Ligand 
binding induces receptor dimerization, trans-phosphorylation and the activation of signal 
transduction cascades (reviewed by van der Geer et al, 1994).  
 
Several other growth factors have also been shown to influence oligodendoroglial 
development in vitro, including insulin like growth factor 1 (McMorris et al, 1986; 
McMorris and Dubois-Dalcq, 1988), epithelial growth factor (EGF) (Sheng et al, 1989) 
and basic FGF (Eccleston and Silberg, 1985; Saneto and de Vellis, 1985, Besnard et al, 
1989).  
 
PDGFRA and its expression during development 
 
The only PDGFR isoform expressed by OPCs is PDGFRA. Since in the CNS, PDGFRA 
is expressed predominately by OPCs (Pringle et al, 1992), it has become one of the 
most commonly used markers for OPCs (Pringle et al, 1989; McKinnon et al, 1990; 
Nishiyama et al, 1996; Dawson et al, 2003). PDGFRA is expressed by OPCs both in 
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vivo (Hart et al, 1989) and in vitro (Hart et al, 1989; McKinnon et al, 1990) and is rapidly 
downregulated in OPCs that start to differentiate (Hart, 1989; Hall, 1996).  
 
PDGFRA is expressed early during development and is one of the earliest markers that 
label cells committed to oligodendrocyte lineage. In the mouse CNS, the first expression 
of PDGFRA is detected around E11, in a restricted region of ventral neuroepithelium 
(Spassky et al, 1998). In the rat CNS, the first PDGFRA transcripts appear around E13 
and it are also restricted to a distinct region of vetral neuroepithelium (Pringle and 
Richardson, 1993; Pringle et al, 1996). The first PDGFRA-expressing cells appear as 
distinct focus, which then spreads out indicating OPC migration away from the VZ. 
PDGFRA expression persists in migrating OPCs, but also those that have settled to 
brain parenchyma. OPCs in the adult brain continue to express PDGFRA.  
 
Similar to PDGF, PDGFRA is critical for OPC development and differentiation. PDGFRA 
disruption in OPCs results in their premature differentiation in culture, whereas OPCs 
from PDGFRA hemizygous mice show impaired proliferation and accelerated maturation 
(McKinnon et al, 2005). Together with the studies that indicate that PDGFRA ligand 
inhibits OPC differentiation (Raff et al, 1985; Noble et al, 1988; Raff et al, 1988; van 
Heyningen et al, 2001), McKinnon study suggests the default pathway that OPCs 
undertake is differentiation. This pathway is normally inhibited by PDGFRA signaling in 
progenitor cells and signaling through PDGFRA needs to be repressed in order for 
OPCs to differentiate. Since PDGFRA is present in OPCs, but gets downregulated as 
OPCs differentiate, it is likely that PDGFRA and its downregulation are critical factors 
that control oligodendrocyte differentiation and that PDGFRA has to be downregulated in 
order for OPCs to differentiate. However, molecular mechanisms that lead to 
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transcriptional repression of PDGFRA and therefore trigger differentiation remain to be 
defined.  
 
PDGFRA regulation 
 
The molecular mechanisms governing the transcription of PDGFRA are poorly 
understood. PDGFRA gene lacks a typical TATA box.  A number of transcription factors 
were shown to regulate PDGFRA transcription in cells that do not belong to 
oligodendrocyte lineage, such as ubiquitously expressed NFkB (Kitami et al, 1995; 
Lindros et al, 1998), C/EBP (Fukuoka et al, 1999; Kitami et al, 1999), Sp1 and Sp3 
(Khachigan et al, 1994; 1995; 1996; Bergeron et al, 2011), but only few transcription 
factors were shown to directly regulate PDGFRA transcription in OPCs.  
 
FGF has been shown to positively regulate PDGFRA transcription, maintain high levels 
of PDGFRA expression and inhibit OPC differentiation (McKinnon et al, 1990) but the 
signaling pathway involved in this regulation is still unclear. Its role in oligodendrocyte 
development is likely complex and involves other signaling mechanisms and 
transcription factors since it has been shown that FGF can regulate PDGFRA 
transcription both positively (McKinnon et al, 1990) and negatively (Bonello et al, 2004). 
 
SoxE family of transcription factors is critical for oligodendrocyte development (Stolt et 
al, 2002; 2003). PDGFRA expression starts with a delay relative to that of Sox9 and 
Sox10 and it is likely that these two transcription factors have a role in the regulation of 
PDGFRA transcription during OPC development. Sox9 has been shown to directly bind 
to PDGFRA gene and positively regulate its expression (Finzsch et al, 2008).  
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Transcription factor Nkx2.2 is expressed in OPCs in the developing mouse spinal cords 
and plays an essential role in the terminal differentiation of oligodendrocytes (Qi et al., 
2001; Zhou et al., 2001). In addition, Nkx2.2 is upregulated in OPCs immediately before 
their differentiation, but rapidly downregulated upon their differentiation (Fu et al., 2002; 
Soula et al., 2001; Xu et al., 2000; Zhou et al., 2001). Its role in oligodendrocyte 
development might involve regulation of PDGFRA expression since Nkx2.2 has been 
shown to directly bind to the 5’	  region of PDGFRA and repress its transcription (Zhu et 
al, 2014).  
 
Posttranscriptional regulation of genes by small noncoding RNAs has become an 
evident factor playing part in many physiological and pathological processes (reviewed 
by Stefani and Slack, 2008). Micro RNAs (miRNAs) are a class of small noncoding 
RNAs that are negative regulators of gene expression at the posttranscriptional level. 
They act either through inhibition of translation or degradation of their target RNAs and 
are able to regulate multiple targets simultaneously (reviewed by Flynt and Lai, 2008). 
Micro RNAs have been shown to play critical role in the development of neurons 
(Visvanathan et al, 2007; Cheng et al, 2009) and oligodendrocytes (Dugas et al, 2010; 
Zhao et al, 2010). One of these miRNAs, miR-219, is induced during OPC differentiation 
and targets negative regulators of differentiation. Its overexpression promoted, while its 
knockdown inhibited OPC differentiation (Dugas et al, 2010; Zhao et al, 2010). In 
addition, miR-219 has been shown to directly bind to Pdgfra mRNA and regulate its 
expression (Dugas et al, 2010). 
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Drug discovery 
 
Discovery and design of new therapeutic chemicals and their development into 
medicines consists of several steps and each has its challenges. The initial difficulty in 
this process arises in the discovery of the lead compound. The lead is a prototype that 
has a number of attractive characteristics (desired biological activity) but may have other 
undesirable characteristics (toxicity, insolubility, metabolism).  
 
Two types of approaches can be taken to identify the lead and they are based on 
random and nonrandom discovery. The first requirement for both approaches is to have 
ways of assaying compounds for desired biological activity. An assay (screen) is done in 
a biological system and can be done both in vitro and in vivo. In vitro assays are quicker 
and less expensive. High throughput screens (HTS) can be carried out robotically in 96, 
384 or 1536 well plates with as little as submicrogram amounts of compound dissolved 
in submicroliter volume. With this approach, it is possible to screen 100,000 compounds 
in a day. HTS appears to have resulted in an increase in the number of hits, but has not 
been resolved yet whether this increase in the hit rate translates to a greater number of 
leads. 
 
Nonrandom screen is performed when the lead has already been discovered. This is 
more focused screen aimed towards compounds that have resemblance to the lead 
compound discovered in random screen. Compounds used for nonrandom screens 
might have only vague structural resemblance to the lead. Even if the lead was shown to 
be only mildly active, screen can uncover lead derivatives that are more potent.  
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In the absence of known leads with desired activity, a random screen is a valuable 
approach. This type of screen involved a large number of compounds of various 
chemical structures. All compounds are screened in the bioassay without regard to their 
structures. Prior to 20th century, this was essentially the only approach because not 
many leads were known. Today, this is still an important approach particularly because it 
is now possible to screen huge numbers of compounds rapidly with HTS. This is also the 
lead discovery method of choice when nothing is known about the receptor target.  
 
Neither random nor nonrandom screens involve rational approaches. However, rational 
approaches that involve designing a compound that has a particular biological activity 
have become an important route in lead discovery. Many diseases are caused by 
imbalance of particular chemicals in the body. Proteins, such as growth factors, 
receptors, enzymes, transcription factors or other members of signaling pathways, are 
common cause for the disruption of the homeostasis of a biological system. This 
imbalance can be corrected by agonism/antagonism of a receptor or activation/inhibition 
of an enzyme. However, for this kind of approach, it is critical to know which protein is 
responsible for this imbalance. This is sometimes difficult to achieve due to complex 
physiological responses that might be caused by disruption of balance.  
 
Drug modifications 
 
Upon discovery of the lead compound, its structure is modified by chemical synthesis to 
amplify the desired activity and to minimize or eliminate the unwanted properties. Even if 
the lead had only weak biological activity, its derivatives might be more potent. Structure 
modifications are the keys to activity and potency manipulations. Activity is the particular 
biological effect, while potency is the strength of that effect. 
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Interactions of drugs with their targets are very specific. Therefore, only a small part of 
the lead, called pharmacophore, may be involved in the interaction. Other residues, 
called auxophores, are also important because they may maintain the integrity of the 
drug, hold the pharmacophore in the correct position or stabilize the interaction between 
pharmacophore and its target. Some residues might have a negative effect and might be 
interfering or destabilizing the interaction. It is important to find out what residues are 
critical for drug action and what need to be removed and this can be determined by 
chemically excising different portions of the lead. 
 
In addition to removal of residues that have negative effect on compounds potency, 
addition of certain residues and structural modifications of the lead can improve lead’s 
physicochemical properties. Such properties include: size, shape, electronic distribution, 
lipid solubility, water solubility, chemical reactivity or hydrogen bonding. As a 
consequence, lead manipulations may cause changes in of the following effects. 
Structural –	  holding of other functionalities in a particular geometry, shape or hydrogen 
bonding. Target interactions –	  interaction with the target.  Pharmacokinetics –	  absorption, 
transport or excretion of the compound. Metabolism –	   blocking or aiding metabolism. 
Since these changes and their effects can reflect on compounds potency in both positive 
and negative manner, multiple modifications may often be necessary to balance the 
effect. 
 
Solubility of compound is one of the critical features that can greatly affect compound 
potency. For each drug to be active, it needs to interact with two environments –	  
aqueous (extracellular space and cytoplasm) and lipophilic (membranes, such as cell 
membrane of blood brain barrier). Low lipophilicity is a great obstacle because it causes 
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poor permeability through membranes. Increased lipophilicity improves compound’s 
permeability and therefore, its accessibility to the target. However, highly lipophilic 
compounds are not efficiently transported through the hydrophilic extracellular media 
and are easily metabolized, which limits their availability. Therefore, there needs to be a 
fine balance between drug’s lipophylicity and hydrophilicity, this depends on compound 
structure and can be achieved by modifying the lead. 
 
Adding or excising CH2 groups can greatly affect drug properties. For many compounds, 
lengthening of a saturated carbon side chain up to nine results in an increase in 
compound potency, while further lengthening causes sudden decrease in potency. This 
is associated with increased lipophilicity of the molecule until its lowered water solubility 
becomes its dominant feature. Chain branching decreases lipophilicity and lowers 
potency, but may also interfere with interaction of the pharmacophore and its target. 
Ionization and low pH lead to increased water solubility since under these conditions, 
compounds’	   residues are protonated and can participate in forming hydrogen bonds 
more easily. 
 
Bioisosteres are substituents that have similar physicochemical and biological 
properties. This is an important lead modification that can fine-tune compound’s 
metabolism, toxicity and potency. One of the common bioisosteric modifications is the 
replacement of hydrogen atom with fluorine at a site of metabolic oxidation in a lead may 
prevent such metabolism from taking place. Because the fluorine atom is similar in size 
to the hydrogen atom the overall topology of the molecule is not significantly altered, 
leaving the desired biological activity unaffected. However, with a blocked pathway for 
metabolism, the drug candidate may have a longer half-life.  
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Structure-activity relationships (SARs) 
 
Structure-activity relationship (SAR) is relationship of the molecular structure of the 
compound and its biological activity. The analysis of SARs provides another way to 
reveal pharmacophore and auxophores.  
 
The hallmark of SAR studies is the synthesis of as many analogs as possible of the lead 
and their testing to determine the effect of structure on activity or potency. Once enough 
analogs are made and tested, conclusions can be made regarding SAR. Ease of 
synthesis rather than logic rationale is often the guiding force behind the choice of 
analogs made. 
 
Upon identifying the critical chemical groups, structure of the lead compound can be 
additionally manipulated in a rationale manner in order to further increase its potency. 
Biological properties of a compound are often a function of its physicochemical 
parameters, such as solubility, lipophylicicty, ionization, stereochemistry, etc. Therefore, 
it is possible to correlate compound structure to its biological effect. This can be used to 
direct the synthesis of lead derivatives. 
 
PDGF signaling in malignancies  
 
Tumors arising from glial cells (gliomas) are the most common forms of primary tumors 
of the CNS. They are among the most deadly types of cancers, but the malignancy 
grade is an essential factor in predicting patient’s outcome. Grade I tumors are treatable. 
However, by the time it is diagnosed, tumor might have progressed to higher grade 
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when even with the most invasive procedures that combine surgery, radiation and 
chemotherapy, patient’s prognosis is weak. 
 
Hyperactivation of RTK signaling pathways is a frequent hallmark of malignant gliomas, 
EGF/EGFR being the most common. Aberrant PDGF signaling has also been 
associated with the development of different types of malignancies, including those 
occurring in the CNS (Hermanson et al, 1992; Di Rocco et al, 1998; Martinho et al, 2009; 
Ozawa et al, 2010; Heldin, 2013). Based on the expression profile, glioblastomas have 
been classified into several categories and mutations of EGFR and PDGFRA define the 
classical and proneural subtypes, respectively (Vehaak et al, 2010). Although PDGFRA 
mutations are not as common as those of EGFR, this still makes PDGFR the second 
most frequently mutated RTK gene in glioblastoma (The Cancer Genome Atlas 
Research Network, 2008). Amplification is the most commonly observed PDGFRA gene 
alteration, while point mutations, deletions and gene rearrangements are rare and occur 
more frequently in glioma samples that already have PDGFRA amplification (Martinho et 
al, 2009; Verhaak et al, 2010; Ozawa et al, 2010). In addition, the expression pattern of 
PDGF and PDGFRs suggest the presence of autocrine and paracrine stimulatory loops, 
which may contribute to tumor progression (Hermanson et al, 1992).  
 
Growing knowledge on the contribution of PDGF signaling in cancer development and 
progression has led to different kinds PDGF signaling inhibitors that target either PDGFs 
of PDGFRs. Antibodies and soluble extracellular parts of the receptors can intervene 
with PDGF signaling by binding to PDGFs or PDGFRs, prevent their interaction or 
promote their degradation (Hawthorne et al, 2008; Shen et al, 2009). However, they are 
expensive and difficult to administer. Small molecule inhibitors of PDGFR are attractive 
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candidates for cancer therapy and are clinically explored (Morris and Abrey, 2010; 
Paulsson et al, 2011). One of the first and most promising drugs, imatinib, has been 
used in the treatment of several cancers (Iqbal and Iqbal, 2014). However, it was shown 
to be unsuccessful in the treatment of CNS malignancies (Reymond et al, 2008), which 
might be due to its limited penetration through the blood brain barrier (Takayama et al, 
2002; Senior, 2003). In addition, imatinib, as well as other small molecule inhibitors, was 
shown to have a broader spectrum of targets, which may contribute to drug’s side effects 
(reviewed by Heldin, 2013).  
 
Small molecule inhibitors, which are currently used for treatment of cancers driven by 
aberrant RTK signaling or evaluated as potential therapies, are directed toward inhibiting 
kinase activity of respective RTKs and were shown to be non-specific. Targeting specific 
RTKs by regulating their expression instead of kinase activity might complement current 
therapies. In addition, design of novel small molecules that are able to cross blood brain 
barrier might provide significant contribution to the treatment of CNS malignancies. 
Since PDGFRA is one of the two most frequently mutated genes in gliomas and since 
PDGFRA signaling pathway plays an important role in tumor development, PDGFRA 
represents a good candidate for targeted therapy. Downregulating its expression at the 
mRNA level might lead to reduction in proliferation of PDGFRA-expressing cells, which 
may limit tumor progression and improve patient’s survival. 
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Chapter 2	  – Identification of small molecule compounds that dow nregulate the 
transcription of PDGFRA in mouse oligodendrocyte progenitor cell line 	  
 
Introduction 
 
PDGFRA signaling is the key regulator of OPC proliferation and differentiation. PDGFRA 
transcription is first detected in a distinct area of VZ early during development (at E11-
E13 in the rodent CNS) and is one of the earliest markers that label cells of 
oligodendrocyte lineage. PDGFRA expression persists in OPCs that have migrated 
away from the subventricular zone and have settled in brain parenchyma. However, as 
OPCs differentiate, PDGFRA gets rapidly downregulated (Hart, 1989; Hall, 1996). 
 
Change in transcription is generally the earliest event that occurs during differentiation. 
Regardless whether downregulation of Pdgfra transcription is the cause or consequence 
of differentiation, we used this change as an indicator of decrease in proliferation and 
increase in differentiation caused by small molecule compounds. 
 
To identify compounds that downregulate Pdgfra transcription we used random screen. 
Compounds were purchased as stocks distributed in 96-well plates. They were tested 
with an assumption that each plate contained compounds of different and random 
structure. Compounds were tested on Oli-neu cells, which represent mouse 
oligodendrocyte precursor cell line. We performed three screens in parallel. Luciferase 
assay was used to indirectly evaluate changes in Pdgfra transcription. In addition to 
quantitative luciferase assay screen, we performed qualitative immunocytochemistry and 
morphology based screens to examine whether compounds promote Oli-neu cell 
differentiation or inhibit their proliferation. We next verified Pdgfra downregulation by 
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assaying the level of endogenous Pdgfra transcript upon treatment with the most 
promising candidate compounds.  
 
Our results revealed a group of small molecule compounds, which structure is derived 
from the lead N-methyl-N-benzylguanidine, that downregulate luciferase activity of 
Pdgfra plasmid in a dose-response manner and inhibit transcription of endogenous 
Pdgfra. 
 
Methods 
 
Cell culture 
 
Oli-neu cells, which represent mouse oligodendrocyte precursor cell line (Jung et al, 
1995), were used for the primary screen as well as verification of hit compounds. Oli-neu 
cells were grown on poly-L-lysine-coated culture dishes. Cells were maintained in growth 
medium consisting of Dulbecco's Modified Eagle Medium/Ham's F-12 (DMEM/F12) 
(Invitrogen) supplemented with 1% horse serum (Hyclone SH30074.03), N2 supplement 
(Invitrogen), 100 U/ml penicillin and 100 µg/ml streptomycin. Addition of 1 mM dibutyryl 
cyclic adenosine 3,5-monophospahte (dbcAMP) (Jung et al, 1995) or dexamethasone 
(DEX) (Joubert et al, 2010) has been shown to induce differentiation of Oli-neu cells 
towards mature oligodendrocytes. To induce differentiation of Oli-neu cells, dbcAMP 
(Sigma) and DEX (Sigma) were added to the culture medium, to 1 mM and 10 μM final 
concentration, respectively. 
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Plasmids 
 
Plasmids were obtained by polymerase chain reaction (PCR), using DNA purified from 
the RP23-412J9 BAC clone as the template and primers listed in table 1. For the 
plasmids PR-111, PR-336, PR-1000 and PR-1595, KpnI and SacI restriction sites 
(underlined in the primer sequence) were incorporated into the forward and reverse 
primers, respectively, to facilitate the cloning of the resulting PCR fragment into the 
pGL4.10 vector (Promega). In order to generate PR-2229 plasmid, XhoI restriction site 
was incorporated into the reverse primer, while the internal SacI site, located 2229 
nucleotides upstream from the TSS, was used for digestion of the PCR fragment at the 
5’	  end. Plasmids were purified with Plasmid Midi Kit (QIAGEN) and the insert position 
and its sequence was confirmed by sequencing using vector backbone primers (vector 
backbone forward primer: GCTGTCCCCAGTGCAAGTGCAGG and vector backbone 
reverse primer: AGTGGGTAGAATGGCGCTGGGCC). 
 
Transfections and luciferase assays 
 
Transfections were carried out using Lipofectamine (Invitrogen) according to 
manufacturer’s instructions. The day before transfection, cells were seeded in 24-well 
tissue culture plates. They were transiently co-transfected with 0.75 μg of the test 
plasmid and 0.05 μg of pGL4.73 vector (Promega) to control for differences in 
transfection efficiencies. As negative control, we used pGL4.10 vector that had no 
Pdgfra insert, while pGL3 promoter (Promega) was used as positive control. Cells were 
split the next day to 96-well plates in order to make triplicates. After allowing cells to 
adhere for 4-6h, they were induced to differentiate. Two days after induction of 
27	  
differentiation, the cells were lysed and the luciferase activities were assessed using a 
DualGlo Luciferase Assay kit (Promega).  
 
Plasmid name	    Primer sequence	   Restriction site	  
Forward primer	   CCGGTACCCAGAGAGCAAGGAGTCCTAGGG Kpn I	  
PDGFRA-111	  
Reverse primer	   CCGAGCTCCTCTCCCTCAAGCTCCAACAG	   Sac I	  
Forward primer	   CCGGTACCCACCCCCAAATTGGGAAGTC	   Kpn I	  
PDGFRA-336	  
Reverse primer	   CCGAGCTCCTCTCCCTCAAGCTCCAACAG	   Sac I	  
Forward primer	   CCGGTACCTTGGTTCCTGGAGTGTCAGC	   Kpn I	  
PDGFRA-1000	  
Reverse primer	   CCGAGCTCCTCTCCCTCAAGCTCCAACAG	   Sac I	  
Forward primer	   CCGGTACCGTGCAAGCCTGTTCGCAGAC	   Kpn I	  
PDGFRA-1595	  
Reverse primer	   CCGAGCTCCTCTCCCTCAAGCTCCAACAG	   Sac I	  
Forward primer	   GACACCCTGGGTTGAGTGAC	   Sac I (internal)	  
PDGFRA-2229	  
Reverse primer	   GGCTCGAGCTCTCCCTCAAGCTCCAACAG	   Xho I	  
 
Table 1. Primers used to make plasmids containing 5’	   Pdgfra sequences of different 
lengths. Plasmid name indicates the position of the starting nucleotide and is relative to 
the transcription start site of the Pdgfra gene. All primers, except the forward primer 
used to make PR-2229, incorporate restriction enzyme digestion sites used to facilitate 
cloning. The position of these sites is underlined. 
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Small molecule compounds 
 
A library of small molecule compounds for the primary screen was purchased from 
Chembridge as 96-well mother plates (plate identification: NT 1147 30941 through NT 
1147 30957) with compounds dissolved in dimethyl sulfoxide (DMSO) as 5 mM stocks. 
Compounds were located in columns 2 through 11 of the 96-well plate, while columns 1 
and 12 contained DMSO and were used as control. Upon identification of potential 
leads, 5 mg of each compound was purchased from Hit2Lead and dissolved in DMSO in 
order to make 50 mM stocks. 
 
Luciferase assay screen 
 
Transfections of Oli-neu cells were carried out using Lipofectamine (Invitrogen) 
according to manufacturer’s instructions. The day before transfection, cells were seeded 
in 6-well tissue culture plates (1.5 million cells/well). They were transiently co-transfected 
with 3.5 μg of PDGFRA-luc plasmid and 0.5 μg of pGL4.73 (Promega) to control for 
differences in the transfection efficiency. Day after transfection, Oli-neu cells were split to 
flat bottom 96-well plates (10,000 cells/well). One well of the 6-well plate would usually 
yield sufficient number of cells for one 96-well plate. Cells were allowed to adhere for 4-
6h when compounds were added at 50 μM concentration. Two days later, DualGlo 
Luciferase Assay (Promega) was performed. 
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Morphology and immunocytochemistry screen 
 
Oli-neu cells were seeded in flat bottom, clear 96-well plates (10000 cells/well). They 
were let to adhere for 4-6h when compounds were added to the final concentration of 25 
μM. Medium was not replaced during the incubation time and no fresh compound was 
added. After 4 days, cells were examined under the light microscope and any changes in 
cell morphology and/or changes in cell density were noted. Oli-neu cells were then fixed 
in wells using 95% ethanol 5% glacial acetic acid and immunostained using O1 antibody. 
Cells were observed with Zeiss Axiovert microscope. 
 
RNA isolation, reverse transcription and quantitative PCR 
 
Oli-neu cells were plated in 6-well plates and treated with selected small molecule 
compounds at 50 μM concentration for 2 days. Total RNA was collected from 500,000 
cells using RNeasy Mini Kit (QIAGEN). An aliquot of the total RNA (1 μg) was then used 
as a template to synthesize cDNA using Superscript III (Invitrogen and according to 
manufacturers recommendations. Quantitative PCR (qPCR) was performed using SYBR 
Green PCR Master Mix (Life Technologies). For each reaction, we used 10 ng of cDNA 
and gene-specific primers listed in table 2. The PCRs were done using the following 
conditions: 2 min at 95°C followed by 39 cycles of denaturation (10s at 95°C), annealing 
and extension (30s at 60°C). The specificity of PCR products was confirmed by the 
analysis of the melting curve. Quantification of gene expression was first normalized to 
GAPDH and then expressed as a logarithm of the ratio of treated to control mRNA level. 
Each amplification reaction was performed three independent times. 	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Gene	   Forward primer	   Reverse primer	  
Gapdh	   TGACAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTGG	  
Pdgfra	   TCGAAGGCAGGCACATTTAC	   TTGAGTCTCCGGATCTGTGG	  
Fgfr1	   CTAACCGCAGAACTGGGATG	   TGGACCAGGAGAGACTCCAC	  
Fgfr3	   TGCACAAGGTCTCTCGCTTC	   TCAGCAGGCAGCTCAAGTTC	  
 
 
Table 2. Primers used for quantification of mRNA in Oli-neu cells in control conditions 
and upon treatment with 50 μM selected compounds. All primers span adjacent exons 
and their specificity was confirmed by melting curve. 
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Results 	  
 
Identification of the PDGFRA-luc plasmid for the screen 
 
In order to identify the most suitable plasmid that we would use in the luciferase 
screening assay, we cloned various lengths of the mouse Pdgfra 5’	   flanking sequence 
into the pGL4.10 vector, which contains cDNA encoding firefly luciferase (FF) (Figure 2. 
A). We next transfected these plasmids into Oli-neu cells and induced the cells to 
differentiate towards oligodendrocytes using 1 mM dbcAMP and 10 μM DEX. Plasmid 
that contains cDNA for renilla luciferase (R) driven by SV40 promoter and enhancer 
(pGL4.73) was used as internal control. As negative control, we used pGL4.10 vector 
that had no Pdgfra insert, while pGL3 promoter (Promega), that contains firefly luciferase 
cDNA driven by SV40 promoter, was used as positive control. DualGlo Luciferase Assay 
was performed two days after induction of differentiation. Plasmid PR-1595, that 
contains 1595 nucleotides of the Pdgfra 5’	   flanking sequence, showed the highest 
luciferase activity and the most robust response to differentiation conditions decreasing 
its activity by ~35%. This plasmid was used for the screen and will be refer to as 
PDGFRA-luc (Figure 2. B). 
 
To identify compounds that inhibit OPC proliferation and stimulate their differentiation, 
we performed 3 primary screens in parallel: luciferase assay, immunocytochemistry 
(ICC) and morphology screens. These screens were all done in Oli-neu cells. 
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Figure 2. Identification of the PDGFRA-luc plasmid for the screen. Various 
lengths of the 5’	   sequence of mouse Pdgfra gene (black lines) were cloned into the 
pGL4.10 vector 5’	  to firefly cDNA (white box). The number in the plasmid name indicates 
the position of the most 5’ nucleotide of the included insert relative to Pdgfra 
transcription start site (TSS), which is indicated as +1 (A). Upon transfection of Oli-neu 
cells and induction of their differentiation, PR-1595, which contains 1595 nucleotides of 
the Pdgfra 5’	  sequence, showed the highest luciferase activity under control conditions 
and the most robust response to differentiation conditions, decreasing its activity by 35% 
(B). This plasmid will be referred to as PDGFRA-luc. # p < 0.001 relative to pGL4.10 
control, * p < 0.001 relative to control, two-way ANOVA, Bonferroni posttest. Error bars 
are standard deviations of the mean.	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Luciferase assay screen 
 
Since Pdgfra downregulation is associated with a decrease in OPC proliferation and 
their differentiation, we used changes in Pdgfra transcription to select for compounds 
that downregulate Pdgfra transcription indirectly, by luciferase assay. 
 
To identify compounds that downregulate PDGFRA-luc activity, we transfected Oli-neu 
cells with PDGFRA-luc and pGL4.73, split them to 96-well plates and treated them with 
small molecule compounds for 2 days at 50	   μM concentration before performing 
luciferase assay.  
 
We tested approximately 1500 compounds in several batches so that 80 (1 plate), 160 
(2 plates) or 320 (4 plates) compounds were tested at the same time. To eliminate day-
to-day variation between experiments, each batch of samples was analyzed at the same 
time, but independently from other batches. Firefly luciferase was normalized to renilla, 
and averages and standard deviations of each batch were determined. To compare 
different batches of samples, normalized luciferase values were converted to standard 
scores (Z scores) using values for averages and standard deviations for each batch of 
samples.  
 
Our results show that out of 1500 compounds tested, 931 downregulated PDGFRA-luc 
activity below the mean. Treatment with 87 compounds resulted in Z score value below  
-1 while 14 compounds had Z scores below -2. None of the compounds had Z score 
below -3. Contrary to that, 589 compounds upregulated PDGFRA-luc activity above the 
mean. Out of these, 125 compounds caused standardized PDGFRA-luc activity to be 
greater than 1, 60 compounds had Z scores above 60, while 33 compounds had Z 
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scores above 3 (Figure 3. A). For further evaluation, we selected compounds that 
resulted in Z score values of -1 and below.  
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Figure 3. Screening for compounds that promote Oli-neu cell differentiation. 
For the luciferase assay based screen, Oli-neu cells were transfected with PDGFRA-luc 
and treated with small molecule compounds at 50 μM for 2 days. Each black dot 
represents standardized (Z score) PDGFRA-luc activity normalized to internal control. All 
compounds that downregulated PDGFRA-luc activity by more than Z = -1 (Z score 
values below the dashed blue line) were selected for further evaluation. Z score = 
(normalized PDGFRA-luc activity –	   mean)/SD (A). For morphology and ICC based 
screens, Oli-neu cells were seeded to 96-well plates and treated with small molecule 
compounds at 25 μM. After 4 days, they were examined for the changes in morphology 
and/or density (C). ICC for O1 revealed compounds that increased the expression of O1 
and/or the percentage of O1+ cells (B). Venn diagram summarizes the results of the 3 
screens: 87 compounds downregulated PDGFRA-luc activity (blue), 146 caused 
changes in Oli-neu cell morphology and/or density (green) and 179 caused an increase 
in the O1 expression and/or the percentage of O1+ cells (red) (D).	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Morphology and immunocytochemistry screen	  
 
In addition to quantitative luciferase assay-based screen, we performed qualitative ICC- 
and morphology-based screens. Oli-neu cells were plated in 96-well plates and treated 
with 1500 small molecule compounds at 25	   μM concentration. After 4 days, we 
examined cell morphology and noted any morphological changes that could indicate 
differentiation (elongation or increased branching of processes) or decrease in the 
proliferation rate (decrease in cell density). Each compound was scored (Figure 3. C). 
Oli-neu cells were then fixed in the same plates and immunostained for O1, a more 
mature marker of oligodendrocyte lineage. We noted and scored compounds that 
caused an increase in the O1 expression, assessed as brightness of the staining relative 
to control, and/or the percentage of O1 positive (O1+) cells (Figure 3. B). Out of 1500 
compounds, 146 caused a change in Oli-neu cell morphology and/or decrease in their 
density, while 179 compounds caused an increase in the O1 expression and/or the 
percentage of O1+ cells. Results of the three screens were summarized (Figure 3. D) 
and all candidate compounds were scored and ranked.  
 
It should be pointed out that since morphology and ICC-based screens were performed 
and analyzed independently from luciferase assay screen, some of the candidate 
compounds identified in these two screens turned out to be upregulators of PDGFRA-luc 
activity. We need to keep in mind that morphology and ICC-based screens were 
performed under different conditions. Most importantly, Oli-neu cells were treated with 
compounds over a longer period of time. Luciferase assay screen detects early changes 
in gene transcription and PDGFRA upregulation could have caused an increase in cell 
survival or initial increase in their proliferation. Primary OPCs were shown to have 
density-dependent control of proliferation (Zhang et al, 1996) and it is possible that a 
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similar mechanism exists in Oli-neu cells. Being an immortalized line, Oli-neu cells have 
a high rate of proliferation that persists over long period of time. However, with 
prolonged or irregular passaging that causes their overgrowth, there might be changes 
in the pattern of expression of several relevant markers, such as O1 (unpublished 
observations). 
 
Verification of luciferase assay screen 
 
From the rank list of all candidate compounds, we selected the top 20 to verify 
downregulation of PDGFRA-luc activity by performing dose-response assays. Similarly 
to the initial luciferase assay screen, Oli-neu cells were transfected with PDGFRA-luc 
and pGL4.73 and split to 96-well plates the day after transfection. We made serial 
dilutions of stock compounds and treated Oli-neu cells at concentrations ranging from 10 
nM to 1 mM. Cells were treated for 2 days when luciferase assay was performed. All 
compounds were citotoxic at 1000 mM and many were citotoxic at 316 μM. Due to 
compound toxicity, assessed either by examining cell morphology or based on the low 
values for renilla luciferase activity measured in the luciferase assay, not all data points 
were included in the dose-response curves. We analyzed dose-response curves and 
determined half maximal inhibitory concentrations (IC50) using GraphPad Prism.  
 
Out of 20 candidates tested, 7 were confirmed and downregulated PDGFRA-luc activity 
in a dose-response manner. Out of these 7 compounds, 3 had similar chemical structure 
(39D11, 40A10 and 40B10). They were derivatives of the lead N-methyl-N-
benzylguanidine (guanidine compounds). The 4th guanidine compound (39E11) altered 
Oli-neu cell morphology and decreased their density, but it caused a modest dose 
dependent decrease in PDGFRA-luc activity. The remaining 4 compounds, that 
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downregulated PDGFRA-luc activity, were not structurally related to each other or to 
guanidine compounds (Figure 4). IC50 for these 8 compounds were shown in Table 3. 
 
Compound	   IC50 range (mM)	  
39D11	   Very wide	  
40A10	   0.01643 to 0.07563	  
40B10	   0.02634 to 0.08656	  
39E11	   Very wide	  
42E8	   Very wide	  
54G2	   0.001429 to 0.004847	  
44C8	   2.974*10-5 to 9162	  
45C11	   3.167*10-7 to 66571	  
 
Table 3. Half maximal inhibitory concentrations for compounds that were verified in the 
dose-response assay. Oli-neu cells were treated with indicated compounds at 
concentrations ranging from 10 nM to 1 mM. Luciferase assay was performed after 2 
days of treatment. GraphPad Prism was used to create and analyze dose-response 
curves. However, due to compound toxicity assessed by examining cell morphology 
under light microscope and renilla luciferase activity, not all data points were included in 
the dose-response curves. Half maximal inhibitory concentrations (IC50) were 
deterimend using GraphPad Prism.	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Figure 4. Verification of the candidate compounds. Oli-neu cells were transfected 
with PDGFRA-luc and pGL4.73 and treated with top 20 candidate compounds selected 
from primary screens. Graphs show normalized luciferase activity as a response to 
different concentrations of compounds. Out of 20 candidates tested, 7 downregulated 
PDGFRA-luc activity in a dose-response manner. Out of these 7 compounds, 3 (39D11, 
40A10 and 40B10) had similar chemical structure based off the lead N-methyl-N-
benzylguanidine (top). Although the 4th derivative of N-methyl-N-benzylguanidine 
(39E11) altered Oli-neu cell morphology in the morphology-based screen, it showed a 
modest dose response effect on PDGFRA-luc downregulation (top). Remaining 4 
compounds, that also resulted in dose-dependent downregulation in PDGFRA-luc 
activity, were not structurally related to N-methyl-N-benzylguanidine or to one another 
(bottom).	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Verification of endogenous Pdgfra transcription dow nregulation	  
 
Since PDGFRA-luc plasmid contains luciferase cDNA and only a portion of the mouse 
Pdgfra gene, downregulation of its activity upon treatment with guanidine compounds 
might not be an accurate reflection of the changes in endogenous Pdgfra transcription. 
Therefore, we examined changes in endogenous Pdgfra mRNA level upon treatment of 
Oli-neu cells with guanidine compounds. Oli-neu cells were seeded in 6-well plates and 
treated with 50 μM compounds for 2 days. As assessed by qPCR, Pdgfra mRNA level 
was ~15 fold lower compared to DMSO control. To the contrary, Pdgfra transcription was 
comparable to DMSO control when cells were treated with 42E8, a non-guanidine 
compound that caused dose-response in PDGFRA-luc activity. We also analyzed the 
changes in mRNA levels of two additional receptor tyrosine kinases (RTKs) expressed 
by OPCs. Changes in transcription for Fgfr1 and Fgfr3 were far less robust compared to 
those of Pdgfra. Compounds 39D11 and 39E11 caused a modest decrease in the level 
of Fgfr1 transcript, while treatment with 40A10 and 40B10 resulted in a marginal 
increase. Contrary to downregulation of Pdgfra transcription, Fgfr3 transcription was 
upregulated upon treatment with guanidine compounds. Fgfr3 transcript level increased 
by approximately 2.5 fold relative to DMSO control (Figure 5). These results suggest that 
downregulation of transcription by guanidine compounds is specific for Pdgfra, and it 
does not occur with other RTKs, such as Fgfr1 and Fgfr3.  	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Figure 5. Changes in endogenous transcription upon treatment w ith guanidine 
compounds. Oli-neu cells were treated with guanidine compounds at 50 μM for 2 days 
when RNA was collected and analyzed. Results of qPCR showed ~15 fold decrease in 
mRNA level of Pdgfra. To the contrary, the transcript level of Fgfr1 showed only marginal 
change, while that of Fgfr3 increased by ~2.5 fold. Each bar represents the average 
result obtained from 3 independent experiments. Error bars are standard errors of the 
mean. (A = amplification factor; dCtC = delta Ct of DMSO control; dCtT = delta Ct upon 
treatment with compounds)	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Discussion	  
 
Results of the primary screens revealed candidate compounds that caused PDGFRA-luc 
downregulation in Oli-neu cells and may have promoted their differentiation. There were 
11 compounds that met our criteria in all three primary screens: they downregulated 
PDGFA-luc activity, caused an increase in O1 expression and altered cell morphology. 
However, 61 compounds met only two out of three criteria. This implies that 
downregulation of PDGFRA-luc does not necessarily correlate with acquisition of mature 
phenotype. This makes sense because it is unlikely that PDGFRA-luc contains all the 
regulatory elements necessary for OPC-specific expression of Pdgfra gene. This is 
further supported by the results obtained during identification of the most suitable 
plasmid for the screen. Although treating Oli-neu cells with inducers of differentiation 
resulted in a decrease in PDGFRA-luc activity, this decrease was only ~35%.  
 
Although luciferase assay has its flaws, such as incomplete regulatory sequences and 
introduction of foreign cDNA into the cell, it is fast and efficient and as such, it represents 
a very useful tool for screening. It would be more informative to run two luciferase assay 
screens in parallel, first using PDGFRA-luc and second utilizing regulatory elements of 
an early oligodendrocyte gene, such as Cnp, which gets upregulated as OPCs 
differentiate into mature oligodendrocytes. A great improvement to the technique would 
be to use stable instead of transient transfections, where the firefly luciferase cDNA is 
driven by regulatory elements of endogenous Pdgfra gene expressed by Oli-neu cells.  
 
Oli-neu cells are immortalized cell line derived from primary mouse OPCs. Although it 
has been shown they are able to generate MAG-expressing cells (Jung et al, 1995), we 
were unable to push them down the oligodendrocyte differentiation pathway further than 
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O1-expressing cell. Contrary to that, a study by Pereira et al (2011) suggests that Oli-
neu cells are father along the differentiation pathway compared to N20.1 cells, which 
represent immortalized oligodendroglial cell line (Verity et al, 1993; Newman et al, 1995; 
Pereira et al, 2011). Whether Oli-neu cells represent immature progenitor cell or early 
oligodendrocyte, this may contribute to low responsiveness of PDGFRA-luc to inducers 
of differentiation. With numerous transgenic mouse lines available, using primary OPCs 
from transgenic mice that have fluorescent reporter driven by endogenous genes of 
oligodendrocyte lineage might provide a better biological system to detect differentiating 
OPCs. 
 
To select candidate compounds after the luciferase assay screen, we calculated 
averages and standard deviations of each batch of samples and selected compounds 
that caused PDGFRA-luc downregulation by at least 1 SD below the average. Using SD 
assumes normal distribution, which does not seem to be the case in our experiment. 
Compounds that caused robust upregulation of PDGFRA-luc activity skewed the 
distribution in their favor. Therefore, this criterion is arbitrarily determined in order to 
establish a cutoff. 
 
Morphology based screen revealed compounds that resulted in a decrease in Oli-neu 
cell density relative to DMSO control or altered their morphology towards a more 
differentiated phenotype. Although the selected compounds might have a desired effect 
inhibiting Oli-neu cell proliferation of promoting their differentiation, we did not run 
consecutive experiments to verify their effect. Therefore, we need to keep in mind that 
the decrease in cell density might be due to partial cytotoxicity of compounds. Similarly, 
change in cell morphology might be caused by cytoskeleton reorganization that is not 
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directly related to differentiation. Therefore, these results need to be interpreted with 
caution and in perspective with results obtained from luciferase assay and ICC screens. 
 
Only 7 out of 20 candidates tested were verified in a dose-response assay. Compounds 
based on N-methyl-N-benzylguanidine structure were further verified with respect to their 
effect on endogenous Pdgfra transcription. A robust downregulation observed in the 
level of Pdgfra transcript contrasts those of Fgfr1 and Fgfr3. This implies that the effect 
of compounds is specific for pathway that regulates Pdgfra transcription and not to those 
that regulate Fgfr1 or Fgfr3 transcription.  	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Chapter 3. Determine structure activity relationship for compounds that 
dow nregulate Pdgfra transcription in Oli-neu cells  
 
Introduction 
 
Drug discovery, especially the one based on random screen, usually does not yield in 
identifying the drug that meets all the criteria we have established. These criteria 
include, but are not limited to (1) desired biological activity, (2) high potency and (3) no 
toxicity. Instead, what is likely to be discovered is the compound that has the desired 
activity, but might have unwanted properties, such as low potency or some degree of 
toxicity. This compound is called “the lead”. After lead has been identified, it is important 
to determine the relationship between leads’	   derivatives and their biological activity 
(structure-activity relationship, SAR). By examining multiple lead derivatives, it is 
possible to find out which residues are critical for maintaining drug properties and which 
can be removed or replaced in order to increase drug potency and diminish its toxicity. 
Determining SAR is often performed by synthesizing as many lead derivatives as 
possible and their testing for biological activity and potency. Structure modifications of 
the lead can be done rationally because compound properties are often based on its 
physicochemical properties, such as solubility and lipophylicity. However, it is usually the 
ease of synthesis that prevails when determining what structure modifications will be 
made. Once sufficient derivatives are tested, conclusions can be drawn regarding SAR. 
 
In order to determine SAR for guanidine derivatives, we first performed structure-based 
screen on an entire Chembridge library, identified all guanidine compounds that were 
included in the library and related their structure to the biological effect they showed in 
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our primary screen. We next synthesized (courtesy of Michael VanHeyst and Dr. Dennis 
Wright) 12 additional guanidine derivatives and tested their effect on PDGFRA-luc 
activity and Pdgfra transcription.  
 
Results of the SAR analysis suggest that the critical positions for modifications of the 
lead N-methyl-N-benzylguanidine, which are required for its biological effect, are 
carbons 2 or 3 of the benzyl ring. Addition of either methyl group or chlorine to carbons 2 
or 3, as well as methoxy group to carbon 2, greatly increases the potency of the lead. 
Elongation of the carbon chain between the nitrogen atom and benzyl ring results in an 
increase in lead’s potency even without the additional modifications. 
 
Methods 
 
Screening 
 
Structure-based screening of the Chembridge library was done using Instant JChem 
5.9.0, 2012 downloaded from ChemAxon website (http://www.chemaxon.com). Library 
was uploaded to Instant JChem and screened based on N-methyl-N-benzylguanidine 
structure. 
 
Guanidine derivatives 
 
Our collaborators, Michael VanHeyst and Dr. Dennis Wright, from the Department of 
Pharmaceutical Sciences synthesized 12 guanidine derivatives that were used in this 
study. Compounds were dissolved in DMSO and their purity was tested using Nuclear 
magnetic resonance (NMR) spectroscopy.  We also examined and compared NMR 
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spectra of newly synthesized compounds to that of compounds purchased from 
Chembridge.  
 
Luciferase assay  
 
Luciferase assay was done as described in Chapter 3 (Methods). Briefly, Oli-neu cells 
were seeded to 6-well plate and transfected with PDGFRA-luc and pGL4.73. They were 
split to 96-well plate the following day and treated with guanidine compounds for 2 days 
at 3 μM and 30 μM. 
 
RNA isolation, reverse transcription and quantitative PCR 
 
RNA isolation, reverse transcription and qPCR were done as described in Chapter 3 
(Methods). Briefly, Oli-neu cells were treated with guanidine compounds for 2 days at 50 
μM. RNA was purified using RNeasy Mini Kit (QIAGEN). An aliquot of 1 μg RNA was 
used for cDNA synthesis using Superscript III (Invitrogen) and 10 ng cDNA was used for 
each qPCR using SYBR Green PCR Master Mix (Life Technologies). Quantification of 
gene expression was first normalized to GAPDH and then expressed as a logarithm of 
the ratio of treated to control mRNA level. Primers used for qPCR: Gapdh (forward 5’- 
TGACAACTTTGGCATTGTGG, reverse 5’-ATGCAGGGATGATGTTCTGG) Pdgfra 
(forward 5’- TCGAAGGCAGGCACATTTAC, reverse 5’- 
TTGAGTCTCCGGATCTGTGG).  
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Results 	  
 
Structure-based screen for derivatives of N-methyl-N-benzylguanidine 
 
Chembridge library contains approximately 100,000 compounds. However, only a small 
portion of approximately 1,500 compounds from the library was used for the primary 
screens in our study. Structure-based screen of Chembridge library revealed only 9 
guanidine derivatives (Figure 6). These compounds were distributed between 2 mother 
plates and both plates happened to be selected for the primary screens. Out of these 9 
compounds, 5 did not show the desired biological effect in any of the primary screens. 
On the other hand, 3 compounds (39D11, 40A10 and 40B10) met the criteria in all 3 
primary screens. The remaining compound (39E11) did not cause decrease in 
PDGFRA-luc activity in the luciferase assay screen, but did cause decrease in Oli-neu 
cell density and change in their morphology.  
 
Analysis of SAR suggests that N-methyl-N-benzylguanidine (compound 39C11) is 
necessary, but not sufficient to induce desired biological activity by itself. Methyl group or 
chlorine potentiates the effect of N-methyl-N-benzylguanidine. However, this occurs only 
if one of these residues is present on either carbon 2 (C2) or carbon 3 (C3) of the benzyl 
ring (Figure 6). 
 
Guanidine compounds dow nregulate PDGFRA-luc activity 
 
In order to further examine the relationship between the differences in structures of 
guanidine compounds and their activity, our collaborators Michael VanHeyst and Dr. 
Dennis Wright from the Department of Pharmaceutical Sciences generated 12 guanidine 
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derivatives, arbitrarily named 001 through 012 (Figure 7. A). The effect of these 
compounds was tested in luciferase assay (Figure 7. B). Oli-neu cells transfected with 
PDGFRA-luc and pGL4.73 were treated with guanidine compounds at 2 concentrations 
that matched 2 data points of previously established dose-response curves (Figure 4). 
None of the compounds caused significant downregulation of PDGFRA-luc activity at 3 
μM relative to control. Different potency of these compounds was more evident when 
Oli-neu cells were treated with higher concentration of compounds. At 30 μM, 002 and 
008 were the most potent and caused significant and most robust downregulation of 
PDGFRA-luc, while 009, 010, 011 and 012 did not downregulate PDGFRA-luc activity. 
Compounds 003, 004, 005 and 007 caused a significant downregulation of PDGFRA-luc, 
although this effect was less robust compared to that of 002 and 008. Finally, treating 
Oli-neu cells with 006 resulted in a marginal decrease in PDGFRA-luc activity that did 
not reach significance. (Figure 7. B). Although structurally identical, 001 and 40A10, as 
well as 007 and 40B10, did not show the same potency. Therefore, our collaborators 
compared the purity of compounds 40B10 and 007 by NMR spectrometry. NMR 
spectrum showed that 40B10 contained traces of an unknown chemical, which might be 
responsible for the more robust effect of 40B10 relative to 007 (not shown). 
 
SAR analysis revealed that replacing benzyl ring with pyridine abolished the biological 
effect of the compound. Compound 005 had stronger effect compared to 007. Therefore, 
the choice of the residue that will be added to C3 of the benzyl ring appears to be 
important in increasing compound’s potency, methyl group being the better choice than 
chlorine. Compound 008 was one of the 2 derivatives that showed the most robust 
downregulation of PDGFRA-luc, which indicates that elongating the guanidine side chain 
increases potency. Finally, addition of methoxy group to C2 of the benzyl ring 
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(compound 002) results in very robust biological effect. However, if methoxy group is 
placed on C3 of the same ring (compound 006), compound’s potency is drastically 
decreased. Compounds 009, 010, 011 that have pyridine in place of benzyl, as well as 
012 that has 2 methoxy groups on C3 and C4 did not alter PDGFRA-luc activity. This 
might be due to increased polarity of these compounds. 
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Figure 6. Structure-based screen for guanidine compounds. Chembridge library 
has approximately 100,000 small molecule compounds out of which only 9 are N-methyl-
N-benzylguanidine derivatives. 39D11, 39E11, 40A10 and 40B10 were selected for 
verification after the primary screens, whereas remaining compounds did not alter either 
PDGFRA-luc activity, Oli-neu cell morphology or O1 expression. Selected 4 compounds 
had either methyl group or chlorine on C2 or C3 of the benzyl ring.	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Figure 7. Structure and potency of guanidine derivatives. Our collaborators from 
the Department of Pharmaceutical Sciences synthesized 12 guanidine derivatives (A, 
courtesy of Micheal VanHeyst and Dr. Dennis Wright). Oli-neu cells were transfected 
with PDGFRA-luc and pGL4.73 and treated with newly generated compounds for 2 days 
at 3 or 30 μM when relative luciferase activity was measured. None of the compounds 
caused significant downregulation of PDGFRA-luc activity at 3 μM. At 30 μM, it was 
evident that compounds have different potencies. Treatment with compounds 002 and 
008 resulted in the most robust downregulation of PDGFRA-luc, while compounds 009, 
010, 011 and 012 did not alter PDGFRA-luc activity. Although structurally identical, 007 
and 40B10 had different potencies (B). Each bar in panel B represents average 
PDGFRA-luc activity normalized to internal control and presented relative to DMSO 
control (100%). * p < 0.05 relative to control, one sample t-test.	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Guanidine compounds dow nregulate endogenous Pdgfra transcription	  
 
Results of the luciferase assay suggest that newly generated guanidine compounds 
downregulate Pdgfra transcription. The next question we asked was whether different 
potency of compounds would be reflected on Pdgfra transcript levels in the same 
manner that was observed in the luciferase assay. To answer this question, we selected 
5 compounds (002, 005, 006, 008 and 012) that had different potency when previously 
tested in the luciferase assay. Compounds 002 and 008 were shown to be the most 
potent in the luciferase assay, while 005 caused significant but less robust effect. 
Compounds 002 and 006 were positional isomers that showed drastically different 
downregulation of PDGFRA-luc, while 012 did not alter PDGFRA-luc. 
 
To determine whether endogenous Pdgfra transcription will follow the trend observed in 
the luciferase assay, Oli-neu cells were treated with selected compounds at 50 μM for 2 
days when RNA was collected and analyzed by qPCR. As expected, changes in Pdgfra 
transcript levels (Figure 8. A) reflected those previously observed in the luciferase assay 
(Figure 8. B). Compounds 002 and 008 caused the most robust decrease in Pdgfra 
transcript levels, while 005 was less potent. Compounds 006 and 012 did not alter 
Pdgfra transcript level.  
 
We also compared the potencies of Chembridge and compounds synthesized by our 
collaborators with respect to their effect on endogenous Pdgfra transcription. Similarly as 
in the luciferase assay (Figure 7), commercial compounds showed greater potency in 
the qPCR assay. Chembridge compounds caused a decrease in the Pdgfra transcript 
level between 10 and 16 fold, while compound 002, the most potent compound 
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generated in Dr. Dennis Wright’s lab, decreased Pdgfra transcript level by less than 9 
fold. Structurally identical 005 and 39E11 also had dramatically different potencies. 
Treatment with 005 resulted in ~3 fold decrease in Pdgfra transcript level, while that with 
39E11 decreased Pdgfra transcript level by ~11 fold (Figure 8. A and C). 
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Figure 8. Changes in endogenous transcription upon treatment w ith guanidine 
compounds. Oli-neu cells were treated with compounds 002, 005, 006, 008 and 012 
(A) or guanidine compounds purchased from Chembridge (C) when RNA was collected 
and changes in Pdgfra transcription were analyzed by qPCR. Changes in Pdgfra mRNA 
levels (A) reflected those observed in the luciferase assay (B). Treatment with 
compounds 002 and 008 resulted in the most robust decrease in Pdgfra transcript level, 
while that with 005 was moderate. Compounds 006 and 012 did not alter Pdgfra 
transcription (A). Commercial compounds however were shown to be more potent 
compared to compounds generated in Dr. Dennis Wright’s lab (C). In panels A and C, 
each bar represents the average result obtained from 3 independent experiments. Error 
bars are standard errors of the mean. dCtC = delta Ct of DMSO control; dCtT = delta Ct 
upon treatment with compounds. In panel B, each bar represents average PDGFRA-luc 
activity normalized to internal control and presented relative to DMSO control. The 
experiment was done in triplicates and error bars are standard deviations. * p < 0.05, 
one sample t-test. 
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Discussion	  
 
Structure based screen of Chembridge library followed by SAR analysis revealed that N-
methyl-N-benzylguanidine is necessary, but not sufficient to induce desired biological 
activity. Addition of methyl group or chlorine potentiates the lead’s effect, but the position 
of these 2 residues is critical. Improvement in compound’s potency occurs only if either 
methyl group or chlorine is present on either C2 or C3 of the benzyl ring. It would be 
interesting to see whether compound’s potency would be further improved if both C2 and 
C3 were occupied by either 2 methyl groups or 2 chlorines or a combination of methyl 
group and chlorine (Figure 9).  
 
SAR analysis of 12 additional derivatives synthesized by our collaborators revealed 
several other pieces of information. (1) Compound 007 showed slightly more robust 
effect compared to that of compound 001 which suggests that addition of chlorine at C3 
instead at C2 of the benzyl ring might be a better choice improving compound’s potency. 
(2) We could not synthesize positional isomer for compound 005 that would have methyl 
group at C2 instead at C3 but the potency of these 2 isomers would be interesting to 
compare. (3) Since compound 004 showed greater potency relative to that of compound 
003, this suggests that removal of methyl group from the nitrogen might further 
potentiate compound’s effect. (4) Presence of methoxy group at C2 (compound 002) 
greatly improves compound’s potency, but this does not happen if the same residue is 
present at C3 (compound 006). (5) Compound 008 is drastically more potent compared 
to 003. This suggests that elongating the chain between guanidine and benzyl ring by 
one carbon might be a critical modification. Such modification might exert its effect by 
increasing compound lipophylicity, stabilizing the compound-target interaction or 
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facilitating the interaction between the pharmacophore and the receptor. Based on SAR 
analysis of Chembridge and compounds generated by our collaborators, we propose 
further modifications that include a combination of selected residues and predict such 
modifications would increase the potency of guanidine compounds (Figure 9). 
 
Replacement of hydrogen atom with fluorine may extend compound’s half-life if such 
replacement was done at the site of metabolic oxidation. Because the fluorine atom is 
similar in size to the hydrogen atom, the overall topology of the molecule is not 
significantly altered, leaving the desired biological activity unaffected. Although structure 
based screen revealed 3 compounds that had such modifications, we did not perform an 
experiment to assess N-methyl-N-benzylguanidine stability and whether such 
modifications would improve it. However, this is something that needs to be kept in mind 
once the top candidates are tested for their biological effect in vivo. 
 
The effect that guanidine compounds exerted on Pdgfra transcript level generally 
followed a similar trend to that observed in the luciferase assay. Compound 002 was the 
most potent in both assays, while 012 did not cause a change in Pdgfra transcription or 
PDGFRA-luc activity. Changes in transcription upon treatment with compounds 005 and 
008 also reflected those observed in the luciferase assay. We were surprised to notice 
treatment with 006 did not alter Pdgfra transcript level although it did cause modest 
decrease in PDGFRA-luc activity that did not reach significance. In addition, for qPCR 
assay, cells were treated with compounds at 50 μM while the highest concentration used 
in the luciferase assay was 30 μM. 
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In both luciferase assay and qPCR assay, commercial compounds were shown to be 
more potent compared to those synthesized by our collaborators. Compounds 005 and 
007 are structurally identical to 39E11 and 40B10, respectively. However, their effects 
on PDGFRA-luc and Pdgfra transcription are drastically different. We examined and 
compared purities of compounds 007 and 40B10 and identified traces of an unknown 
chemical, which might be responsible for the difference in the effect we have observed. 
It would be interesting to identify this chemical or separate it from N-methyl-N-(3-
chlorinebenzyl) guanidine using column chromatography and analyze its effect 
independently from guanidine compound. Although we did not compare the purities of 
compounds 005 and 39E11, it is likely 39E11 contains compound other than N-methyl-
N-(3-methylbenzyl) guanidine. Whether this is true as well as the nature of 
contaminating compound remains to be identified. 
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Figure 9. Predicted structural modifications of N-methyl-N-benzylguanidine 
that w ould result in its increased potency. SAR analysis of Chembridge and 
compounds synthesized by our collaborators revealed that the following modifications of 
N-methyl-N-benzylguanidine increase its potency: addition of methyl group or chlorine to 
C2 or C3 of the benzyl ring, addition of methoxy group to C2, removal of the methyl 
group from the nitrogen atom of the guanidine group and elongation of the carbon chain 
between the nitrogen atom of the guanidine group and benzyl ring. We predict that a 
combination of such modifications, generating structures shown in this figure, would 
result in a further increase in N-methyl-N-benzylguanidine potency. Such modifications 
are illustrated on this figure. Addition of a residue (chlorine, methyl or methoxy group) to 
the carbon atom of N-methyl-N-benzylguanidine is indicated by an arrow, removal of the 
methyl group from the nitrogen atom is indicated by an arrowhead, while asterisk marks 
elongation of the carbon chain.	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Chapter 4	  – Determine w hether the compounds promote OPC differentiation.	  
 
Introduction 
 
PDGF signaling is the major regulator of OPC proliferation and differentiation. Studies 
have implied that it has to be inhibited in order for OPC differentiation to occur (Noble et 
al, 1988; McKinnon et al, 2005). In vitro, this can be achieved by PDGF removal from the 
culture medium (Raff et al, 1985; Raff et al, 1988) or blockage with anti-PDGF antibodies 
(Richardson et al, 1988; Noble et al, 1988). In vivo, PDGF knockout results in decreased 
number of OPCs (Fruttiger at al, 1999). OPCs from PDGFRA knockout mice undergo 
accelerated maturation and the onset of differentiation appears to depend on the Pdgfra 
gene dose (McKinnon et al, 2005). PDGFRA is rapidly downregulated as OPCs 
differentiate (Hart, 1989; Hall, 1996) and we used the downregulation of its transcription 
as putative indicator of differentiation.  
 
Here, we wanted to examine whether guanidine compounds, identified in the primary 
screen and verified as downregulators of Pdgfra transcription in Oli-neu cells, promote 
Oli-neu and OPC differentiation. To answer this question, we used Oli-neu cells and 
dissociated culture of primary rat OPCs and examined the changes in transcription of 
OPC- and oligodendrocyte-specific genes upon treatment with guanidine compounds. 
We also examined whether treatment of primary rat OPCs with guanidine compounds 
would result in an increase in the percentage of differentiating identified by O1 antibody. 
Our results show that, although compounds cause a decrease in the level of Pdgfra 
transcript, they are do not upregulate transcription of more mature markers of 
oligodendrocyte lineage or the percentage of O1+ primary rat OPCs. 
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Methods 
 
Dissociated cultures of primary rat OPCs 
 
Mixed glial cultures were prepared as descried previously (Yang et al, 2005). Briefly, 
cerebral cortices from P2-P4 CD rats (Charles River Laboratories) were dissected out, 
minced, triturated and plated in 75 cm2 culture flasks coated with 30 μg/ml poly-L-lysine 
(Sigma). Cell cultures were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
(Gibco 11960) containing 10% FBS (Gibco 26140) at 37°C in humidified air with 5% 
CO2. After 6-8 days, loosely attached cells were shaken-off and preplated for 30 
minutes in order to eliminate contaminating astrocytes and microglia from cells of 
oligodendrocyte lineage. The non-adherent cells were collected, resuspended in 
immunopanning buffer containing Dulbecco's phosphate-buffered saline (DPBS) (Gibco 
14287), 0.02% bovine serum albumin (BSA) (Sigma A-4161), 5 μg /ml insulin (Sigma I-
6634), and plated in petri dishes coated with monoclonal O1 antibody in order to 
separate mature oligodendrocytes from OPCs. Cells that did not adhere to the dish were 
collected and plated in petri dishes coated with O4 monoclonal antibody. Purified OPCs 
were resuspended in Sato’s medium: DMEM (Gibco 11960), 2 mM L-glutamine (Gibco 
25030), 1X penicillin/streptomycin (Gibco 15140), 100 μg/ml transferrin (Sigma T-1147), 
100 μg/ml BSA (Sigma A-4161), 16 μg/ml putrescine (Sigma P-5780), 60 ng/ml 
progesterone (Sigma P8783), 40 ng/ml sodium selenite (Sigma S5261), 5 μg/ml N-acetyl 
cysteine (Sigma A8199), 1 mM sodium pyruvate (Gibco 11360), 1X trace elements B 
(Cellgro 99-175-CI), 10 ng/ml D-biotin (Sigma B4639), 5 μg/ml insulin (Sigma I-6634), 5 
μM forskolin (Sigma F6886), 10 ng/ml CNTF (Peprotech 450-13), 1 ng/ml neutrophin 3 
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(NT3) (Peprotech 450-03). OPCs were then plated in poly-L-lysine coated tissue culture 
plates in the medium containing 20 ng/ml mouse PDGF (Peprotech 100-13A).  
 
Immunocytochemistry  
 
After positive selection of O4-expressing OPCs, cells were resuspended in Sato’s 
medium and were plated in poly-L-lysine coated tissue culture plates in medium 
containing 20 ng/ml mouse PDGF (Peprotech 100-13A). They were allowed to 
proliferate for 2 days when they were trypsinized and split to coverslips coated with 100 
μg/ml poly-L-lysine at the density of 5,000 cells/coverslip. They were kept in medium 
containing 5 ng/ml mouse PDGF (Peprotech 100-13A). For differentiation experiments, 
either T3 (Sigma T6397) or compounds were added to the final concentration of 400 
ng/ml and 10 μM, respectively. They were treated for 2 days before fixing with 4% 
paraformaldehyde (PFA) and staining for O1.  
 
RNA isolation, reverse transcription and quantitative PCR 
 
RNA isolation, reverse transcription and qPCR for transcripts expressed by Oli-neu cells 
were done as described in Chapter 3 (Methods). Briefly, Oli-neu cells were treated with 
guanidine compounds for 2 days at 50 μM. RNA was purified using RNeasy Mini Kit 
(QIAGEN). An aliquot of 1 μg RNA was used for cDNA synthesis using Superscript III 
(Invitrogen) and 10 ng cDNA was used for each qPCR using SYBR Green PCR Master 
Mix (Life Technologies). Quantification of gene expression was first normalized to 
GAPDH and then expressed as a logarithm of the ratio of treated to control mRNA level. 
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Primary rat OPCs used for qPCR were obtained from P4 rat cortices by 
immunoselection using anti-O1 and goat anti-mouse PDGFRA antibodies. After 
selection of PDGFRA expressing cells, OPCs were resuspended in Sato’s medium 
supplemented with 20 ng/ml mouse PDGF (Peprotech 100-13A), plated in poly-L-lysine 
coated tissue culture plates and allowed to proliferate for 3 days. Approximately 50% of 
medium was removed every day and replaced with 50% of fresh culture medium. On the 
3rd day, OPCs were trypsinized and resuspended in Sato’s medium that contained 5 
ng/ml mouse PDGF. They were split to poly-L-lysine coated tissue culture dishes. To 
promote differentiation, either 400 ng/ml T3 or 10 μM 39D11 were added to the culture 
medium. Cells were treated for 2 days before RNA was extracted from approximately 
250,000 cells using RNeasy Mini Kit (QIAGEN). An aliquot of 1 μg RNA was used for 
cDNA synthesis using Superscript III (Invitrogen) and 10 ng cDNA was used for each 
qPCR using SYBR Green PCR Master Mix (Life Technologies). The PCRs were done 
using the following conditions: 2 min at 95°C followed by 39 cycles of denaturation (10s 
at 95°C), annealing and extension (30s at 60°C). Quantification of gene expression was 
first normalized to GAPDH and then expressed as a logarithm of the ratio of treated to 
control mRNA level. 
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Gene	   Forward primer	   Reverse primer	  
Mouse Gapdh	   TGACAACTTTGGCATTGTGG ATGCAGGGATGATGTTCTGG	  
Mouse Pdgfra	   TCGAAGGCAGGCACATTTAC	   TTGAGTCTCCGGATCTGTGG	  
Mouse Cspg4	   GGCCTTGTTGGTCAGATCTACAG	   GCAGCAGGTCTACTCTGGTCAGA	  
Mouse Olig2	   TTACAGACCGAGCCAACACC	   GATGGGCGACTAGACACCAG	  
Mouse Sox10	   TACCCTCACCTCCACAATGC	   AGTCCGGATGGTCCTTTTTG	  
Mouse Cnp	   GCCAGGTCTTTCTGGAGGAG	   TTGTACAGTGCAGCACACCTG	  
Mouse Mbp	   ACACACGAGAACTACCCATTATGG	   TGTTCGAGGTGTCACAATGTTCTT	  
Mouse Gfap	   GATCTATGAGGAGGAAGTTCGAGAA	   CGTATTGAGTGCGAATCTCTCTCA	  
Rat Gapdh	   TAGAGACAGCCGCATCTTCTTG	   CGTTGATGGCAACAATGTCC	  
Rat Pdgfra	   TTGGAGCTTGAGGGAGTGAAAC	   AGACAGCTGAGGACCAGAAAGG	  
Rat Cspg4	   TTACAAGTCCAGACGCCCAAC	   GTTCTCCCCGAAGAAGGAGG	  
Rat Mbp	   AAATCGGCTCACAAGGGATTC	   AGGATTCGGGAAGGCTGAG	  
 
 
Table 4. Primers used for quantification of mRNA in Oli-neu cells and primary rat OPCs 
in control conditions and upon treatment with guanidine compounds. All primers span 
adjacent exons and their specificity was confirmed by melting curve.	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Antibodies	  
 
Immunoselection of primary rat OPCs for immunocytochemistry was done with the 
following antibodies: secondary antibody used for coating petri dishes was goat anti-
mouse IgM μ chain specific in 50mM Tris-HCl pH 9.5 (Jackson Immunoresearch 115-
005-020) at 1 μg/ml in, while the primary antibodies were mouse anti-O1 and anti-O4 
supernatant obtained from Dr. S. Pfeiffer (Farmington, CT) at 1:1 dilution in PBS with 
0.2% BSA. For immunostaining, we used mouse anti-O1 (Dr. S. Pfeiffer) at 1:1 dilution in 
PBS with 5% normal goat serum (NGS) and Cy3 conjugated donkey anti-mouse IgM, µ	  
chain specific (Jackson Immunoresearch 715-165-020). Immunoselection of primary rat 
OPCs for qPCR was done with the following antibodies: secondary antibody used for 
coating petri dishes was donkey anti-goat IgG (Jackson Immunoresearch 705-006-147), 
while the primary antibody was goat anti-mouse PDGFRA (R&D Systems). Antibodies 
were dissolved in 50 mM Tris-HCl pH 9.5 at 1 μg/ml. 
 
Results 
 
Guanidine compounds do not promote differentiation of primary rat OPCs 
 
Results of the primary screen indicated that guanidine compounds cause an increase in 
O1 expression and change Oli-neu cell morphology towards a more mature phenotype. 
Therefore, we hypothesized that they will also promote differentiation of primary OPCs. 
To test this hypothesis, we used primary rat OPCs purified from neonatal rat cortices. 
OPCs were plated on coverslips in the medium that contained 5 ng/ml PDGF. They were 
treated with 10 μM compounds on the same day, while addition of 400 ng/ml T3 to the 
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culture medium was used as positive control. After 2 days, cells were fixed and stained 
for O1. Under differentiating conditions (medium supplemented with T3), the percentage 
of O1+ cells increased by approximately 3 fold. In addition, O1+ cells acquired different 
morphology. While O1+ cells under control conditions were small and had short 
processes, ones treated with T3 had longer and more branched processes as well as 
lamellipodia. Several guanidine compounds caused a change in OPC morphology, 
which resembled that observed when cells were treated with T3, but the length and 
branching of processes was less extensive compared to the T3 control (non-quantified 
observations). However, although several compounds caused an increase in the 
percentage of O1+ cells, this increase did not reach significance (Figure 10. B). 
 
Changes in transcription occur before progenitor cells acquire differentiated phenotype. 
Although treatment with guanidine compounds did not cause a significant increase in the 
percentage of O1+ cells, we wanted to examine whether it would cause a change in 
Pdgfra, Ng2 or Mbp transcript levels (Figure 10. C). Although Pdgfra transcript level 
decreased upon treatment with 39D11, this decrease was marginal. Mbp transcript level 
also showed a slight decrease, while that of Ng2 increased. Taken together, these 
results do no support our hypothesis that guanidine compounds promote differentiation 
of primary rat OPCs. 
 
Guanidine compounds do not upregulate transcription of more mature 
oligodendrocyte markers in Oli-neu cells 
 
We used Oli-neu cells treated with 50 μM compounds for 2 days to analyze the 
endogenous transcription of several genes which expression changes during OPC 
differentiation. As OPC differentiate toward mature oligodendrocytes, Pdgfra and NG2 
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transcription decreases, while that of Cnp and Mbp increases. Olig2 and Sox10 are 
transcription factors that persist throughout an entire oligodendocyte lineage. Therefore, 
their transcript levels would not show a dramatic change. When induced to differentiate, 
Oli-neu cells were also shown to upregulate more mature markers of oligodendrocyte 
lineage, such as Cnp, Mbp and Plp (Joubert et al, 2010). Our qPCR results showed that 
Pdgfra transcript indeed follows the expected transcriptional changes when Oli-neu cells 
were treated with guanidine compounds. All commercially available guandine 
compounds caused a decrease in Pdgfra transcript level, while non-guanidine 
compound (42E8) did not cause a change in transcription (Figure 11. A). Similarly to 
Chembridge compounds, guanidine derivatives synthesized by our collaborators also 
caused a decrease in Pdgfra transcription and showed different potencies (Figure 11. B). 
However, Ng2 transcript level showed only marginal decrease when treated with 
Chembridge compounds. Contrary to Chembridge compounds, treatment with 002, 005, 
006 and 008 caused a slight increase in Ng2 transcription. Changes in Sox10 transcript 
levels were similar to that of Ng2. Unexpectedly, Cnp transcription was decreased upon 
treatment with guanidine compounds while that of Mbp was marginally decreased upon 
treatment with Chembridge compounds and marginally increased upon treatment with 
002, 005, 006 and 008. Surprisingly, Olig2 transcription was robustly inhibited when Oli-
neu cells were treated with both sets of guanidine compounds (Figure 11. A and B).  
 
When treated with FBS in culture, both primary OPCs and Oli-neu cells were shown to 
downregulate OPC-specific genes and upregulate astrocyte genes. Therefore, we asked 
whether guanidine compounds induce Oli-neu cell differentiation toward astrocytes, 
rather than oligodendrocytes. The trend we observed examining transcript levels of OPC 
and oligodendrocyte markers would support this hypothesis. Therefore, we looked at 
changes in transcription of glial fibrillary acidic protein (Gfap), which is a commonly used 
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marker for astrocytes (Bignami et al, 1972). Our qPCR results showed that compounds 
002, 005, 006 and 008 caused a 2-fold increase in the Gfap transcript level (Figure 11. 
B). However, when Oli-neu cells were treated with commercial compounds, Gfap 
transcription was comparable to control (Figure 11. A). Taken together, these results 
suggest that although guanidine compounds downregulate Pdgfra transcription, they do 
not promote differentiation of OPCs to oligodendrocytes or astrocytes. 
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Figure 10. Differentiation of primary rat OPCs upon treatment w ith guanidine 
compounds. Purified rat OPCs were treated with 10 μM compounds for 2 days before 
they were immunostained for O1 (A). Quantification showed that addition of T3 resulted 
in a significant increase in the percentage of O1+ cells among all cells. Although several 
guanidine compounds caused a slight increase in the percentage of O1+ cells, this 
increase was modest and did not reach significance. (C) Primary rat OPCs, maintained 
in the medium that contained 5 ng/ml PDGF, were treated either with T3 or 39D11 at 
400 ng/ml or 10 μM, respectively. After 2 days of treatment, RNA was collected and 
changes in transcription were analyzed by qPCR. dCtC = delta Ct of DMSO control; 
dCtT = delta Ct upon treatment with compounds. * p<0.05, two sample t-test relative to 
control.	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Figure 11. Changes in endogenous transcription upon treatment w ith 
guanidine compounds. Oli-neu cells were treated with 50 μM guanidine compounds, 
which were either purchased from Chembridge (A) or synthesized by our collaborators 
(B). After 2 days of treatment, RNA was collected and changes in transcription were 
analyzed by qPCR. Each bar represents the average result obtained from 3 independent 
experiments. Error bars are standard errors of the mean. dCtC = delta Ct of DMSO 
control; dCtT = delta Ct upon treatment with compounds. 	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Discussion	  
 
PDGFRA is rapidly downregulated as OPCs differentiate. Therefore, we hypothesized 
that downregulation of Pdgfra transcription caused by guanidine compounds would 
correlate with increase in Oli-neu and OPC differentiation.  
 
Differentiation of OPCs was assessed by quantification of the percentage of O1+ cells, 
qualitative examination of cell morphology and qPCR. Although there was a slight 
decrease in the Pdgfra transcript level when cells were treated with 39D11, this 
decrease was less than 2-fold. Surprisingly, Mbp transcript level was decreased as well, 
but marginally. We did not observe a significant increase in the percentage of O1+ cells 
with any of the compounds. Several guanidine compounds seemed to have caused a 
change in cell morphology similar to that observed when OPCs were treated with T3 but 
of far less extent. All this suggests that treatment with guanidine compounds is not 
sufficient to induce differentiation of primary rat OPCs under the conditions we used. 
PDGF has been shown to be a potent mitogen for OPCs but also suggested as an 
inhibitor of their differentiation (Noble and Murray, 1984; Noble et al, 1988; Richardson 
et al, 1988; Raff et al, 1988; Pringle et al, 1989, McKinnon et al, 1990; Raff et al, 1988; 
Pringle et al, 1989; Richardson et al, 1988; Noble et al, 1988). When OPCs are treated 
with 10 ng/ml PDGF, they proliferate over a period of several days (Noble et al, 1988, 
Richardson et al, 1988). However, upon PDGF withdrawal, they rapidly differentiate 
(Raff et al, 1983; Noble, 1984; Temple, 1985). All this suggests that PDGF signaling 
needs to be finely balanced in order for differentiation to occur under given conditions. It 
is possible that lowering concentration of PDGF to 5 ng/ml was sufficient to induce 
differentiation of primary OPCs by itself and that treatment was 10 μM compounds was 
not sufficient to accelerate the differentiation process. Another possibility is that even 5 
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ng/ml PDGF caused an inhibition of OPC differentiation that could not be overridden by 
addition of 10 μM guanidine compounds. 
 
Differentiation of Oli-neu cells along the oligodendrocyte lineage was assessed by 
examining changes in endogenous transcription upon treatment with guanidine 
compounds. Pdgfra transcript levels decreased upon treatment with guanidine 
compounds. Unexpectedly however, Cnp transcription is inhibited as well. Although 
some studies have implied that Olig2 gets downregulated in mature oligodendrocytes 
(Ligon et al, 2006), ~15 fold decrease in Olig2 transcript level upon treatment with 
guanidine compounds after only 2 days of treatment should not be attributed solely to 
differentiation. Decrease in the transcript level of all oligodendrocyte-specific markers 
observed upon treatment with Chembridge compounds might be explained by OPC fate 
switch to astrocytes. However, this does not seem to be the case here since Gfap 
transcript level is only marginally increased. 
 
Taken together, our results suggest that although the transcript level of Pdgfra, one of 
the critical factors that regulates differentiation of OPCs, gets dramatically 
downregulated upon treatment with guanidine compounds, this event is not sufficient for 
differentiation to occur under given conditions. It is possible that guanidine compounds 
target a specific receptor or pathway, but there are factors that need to be regulated at 
the same time in order for successful differentiation to occur. This is supported by the 
fact that there is a discrepancy between the effects observed when cells were treated 
with Chembridge compounds compared to those when our own compounds were used. 
Sample 40B10 contains traces of an unknown chemical, which might be responsible for 
the inconsistent regulation of Ng2, Sox10 and Mbp transcripts. A combination of 
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guanidine derivatives, which downregulate Pdgfra, with other compounds, that cause an 
upregulation of Cnp and Mbp, might bring us closer to our goal. 
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Chapter 5 - Determine w hether the compounds inhibit OPC proliferation.	  
 
Introduction 
 
The roles of PDGF and PDGFRA in OPC proliferation and differentiation have been 
extensively studied. Numerous studies have shown that PDGF is the major mitogen for 
OPCs both in vitro and during development (Noble and Murray, 1984; Noble et al, 1988; 
Richardson et al, 1988; Raff et al, 1988; Pringle et al, 1989, McKinnon et al, 1990; Raff 
et al, 1988; Pringle et al, 1989; Richardson et al, 1988; Noble et al, 1988; van Heyningen 
et al, 2001). PDGF withdrawal from the culture medium or its block with anti-PDGF 
antibodies is sufficient to induce OPCs to exit cell cycle and differentiate (Raff et al, 
1985; Raff et al, 1988; Richardson et al, 1988; Noble et al, 1988). PDGF exerts its 
effects though PDGFRA, which is the only PDGFR isoform expressed by these cells 
(Pringle et al, 1992; Nishiyama et al, 1996; Dawson et al, 2003). PDGFRA disruption in 
OPCs results in their premature differentiation in culture, whereas OPCs from PDGFRA 
knockout mice show impaired proliferation (McKinnon et al, 2005). Since PDGFRA is 
critical for OPC proliferation, we hypothesized that downregulating its transcription by 
guanidine compounds would result in decrease in OPC proliferation. 
 
We tested the effect of guanidine compounds on the proliferation of PDGFRA-
expressing Oli-neu cells and primary mouse OPCs, as well as HEK 293 cells and 
primary mouse astrocytes that do not express PDGFRA. We also examined the 
proliferation of three glioblastima-derived cell lines that show different levels of PDGFRA 
transcript (Lokker et al, 2002). Our results show that guanidine compounds robustly 
inhibited proliferation of Oli-neu cells and primary mouse OPCs, while they did not alter 
proliferation of HEK 293 cells and primary mouse astrocytes. Surprisingly, all 
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glioblastoma-derived cell lines showed a very mild decrease in proliferation and their 
response that did not correlate with the amount of PDGFRA transcript present. Contrary 
to Oli-neu cells and OPCs, guanidine compounds did not downregulate PDGFRA 
transcription in glioblastoma-derived cell lines.  
 
Methods 
 
Cell culture 
 
Oli-neu cells were grown on poly-L-lysine-coated culture dishes. Cells were maintained 
in growth medium consisting of DMEM/F12 (Gibco 11330) supplemented with 1% horse 
serum (Hyclone SH30074.03), N2 supplement (Gibco 17502), 1X penicillin/streptomycin 
(Gibco 15140). Glioblastoma-derived cell lines A172, U251 and T98G, as well as HEK 
293 cells were grown in DMEM (Gibco 11960) supplemented with 10% FBS (Gibco 
26140), 2 mM L-glutamine (Gibco 25030), 1X penicillin/streptomycin (Gibco 15140). All 
cell cultures were maintained at 37°C in 5% CO2 in a humid atmosphere. 
 
Mixed glial cultures were prepared as descried previously (Yang et al, 2005). Briefly, 
cerebral cortices from P2-P4 FVB mice (Jackson Laboratory) were dissected out, 
minced, triturated and plated in 25 cm2 culture flasks coated with 30 μg/ml poly-L-lysine 
(Sigma). Cell cultures were maintained in DMEM (Gibco 11960) containing 10% FBS 
(Gibco 26140) at 37°C in humidified air with 5% CO2. After 6-8 days, loosely attached 
OPCs and microglia were shaken-off. Remaining astrocytes were trypsinized, collected 
and plated on coverslips coated with 100 μg/ml poly-L-lysine at 5000 cells/coverslip. 
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Primary mouse OPCs were obtained from P2 mouse cortices from FVB mice by 
negative immunoselection using mouse anti-O1 and positive immunoselection using rat 
anti-mouse PDGFRA (BD Pharmingen). PDGFRA positive cells were resuspended in 
Sato’s medium supplemented with 50 ng/ml mouse PDGF (Peprotech), plated in poly-L-
lysine coated tissue culture dishes and allowed to proliferate for 3 days. Approximately 
50% of medium was removed every day and replaced with 50% of fresh culture medium. 
On the 3rd day, OPCs were trypsinized and resuspended in Sato’s medium that 
contained 20 ng/ml mouse PDGF. They were plated in coverslips coated with 100 ug/ml 
poly-L-lysine.  
 
For proliferation experiments, cells were split to coverslips and treated with 50 μM 
guanidine compounds for 2 days. EdU (Life Technologies C10337) was added to the 
culture medium during the last 5h of incubation at the concentration of 10 μM. Cells were 
then fixed with 4% PFA and immunostained. Click-iT EdU Alexa Fluor 488 Imaging Kit 
(Life Technologies C10337) was used to label EdU+ cells. 
 
Slice culture 
 
Cortical organotypic slice cultures were prepared from P7-P8 NG2creBAC:ZEG double 
transgenic mice (Zhu et al, 2008) as described previously (Bahr et al, 1995; Zhu et al, 
2011; Hill et al, 2013). Briefly, 300 μm coronal forebrain slices were cut with a tissue 
chopper and placed on Millicell culture inserts (Millipore PICM03050). Slices were 
maintained at 37°C in 5% CO2 in a humid atmosphere. Slice medium contained 50% 
Minimal Essential Medium with Earle’s Salts (MEM) (Gibco 11090), 25 mM HEPES 
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(Sigma H-4034) buffer at pH 7.22, 25% Hank’s balanced salt solution (HBSS) (Gibco 
14175), 25% horse serum (Hyclone SH30074.03), 0.4 mM ascorbic acid (Sigma A-
0278), 1 mM L-glutamine (Gibco 25030) and 1 μg/ml insulin (Sigma I-6634). 
 
For proliferation experiments, slices were treated with 1 μM or 10 μM guanidine 
compounds for 2 days in the medium that either had or did not have 50 ng/ml human 
PDGFAA (R&D Systems 221-AA). EdU was added to the slice medium during the last 
5h of incubation at the concentration of 10 μM. Slices were then fixed and EdU+ were 
detected with Click-iT EdU Alexa Fluor 488 Imaging Kit (Life Technologies C10337). 
 
Citotoxicity assay and flow cytometry 
 
After 16h treatment with MMC or 50 μM guanidine compounds, Oli-neu cells were 
harvested. Apoptotic cells were detected using Alexa Fluor 488 Annexin V/Dead Cell 
Apoptosis Kit (Life Technologies V13241) according to manufacturer’s instructions with 
one modification. After incubating cell suspension with Alexa Fluor 488 Annexin V and 
propidium iodide, samples were washed once with 1 ml PBS in order to remove excess 
dye. Immediately following staining 10,000 cells were counted and analyzed with flow 
cytometry (BD FACSCalibur flow cytometer, Biotechnology-Bioservices Center, 
University of Connecticut, Storrs). Analysis was done using FlowJo software. 
 
To compare the effect of guanidine compounds on proliferation and toxicity, Oli-neu cells 
were treated with 50 μM compounds for 16h with addition of EDU during the last 4h of 
treatment. Then they were harvested, resuspended in PBS and fixed by addition of PFA 
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to the final concentration of 2%. After washing once with PBS, pellets were resuspended 
in 50 ul Click-iT reaction cocktail (Life Technologies C10337). After 30 min, suspension 
was diluted to 500 ul with PBS. Cell pellets were collected, resuspended in 500 ul PBS 
and analyzed with flow cytometry (BD FACSCalibur flow cytometer, Biotechnology-
Bioservices Center, University of Connecticut, Storrs). Analysis was done using FlowJo 
software. 
 
Results 
 
Guanidine compounds inhibit proliferation of Oli-neu cells  
 
We previously demonstrated that 002, 005 and 008 caused a decrease in Pdgfra 
transcript level, 002 having the most robust effect, whereas 006 and 012 did not alter 
Pdgfra transcription (Chapter 5). Since PDGFRA gets downregulated with induction of 
differentiation, decrease in Pdgfra transcription might correlate with decrease in Oli-neu 
proliferation. In addition, we observed a striking difference in cell density when Oli-neu 
cells were treated with guanidine compounds (Figure 12. A). We therefore wanted to 
examine the possibility that the decrease in cell density is due to inhibition of 
proliferation. For this purpose, we treated Oli-neu cells with guanidine derivatives 002, 
005, 006, 008 and 012 for 2 days at 50 μM concentration and assayed the percentage of 
proliferating cells during the last 5h of treatment (Figure 12. B and C). As expected, 
compounds 002, 005 and 008 caused a dramatic decrease in proliferation, assayed by 
the percentage of PDGFRA+/EDU+ among all PDGFRA+ cells. Surprisingly, although 
006 did not inhibit Pdgfra transcription, treatment with 006 resulted in a significant 
decrease in the percentage of proliferating cells. When cells were treated with 012, there 
was a marginal decrease in proliferation that did not reach significance. 
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Quantitative PCR was performed in order to assess transcript levels of cyclin-dependent 
kinase inhibitors p21Cip1 (p21) p27Kip1 (p27), which were shown to be upregulated as 
OPCs are exiting the cell cycle (Casaccia-Bonefil et al, 1997; Durand et al, 1997; Ghiani 
et al, 1999). Our results showed that 002 caused the most robust increase in p21 and 
p27 transcript levels, while 005 and 008 caused somewhat moderate increase. 
Surprisingly, compound 006 resulted in less than 2-fold increase in transcript levels of 
p21 and p27 (Figure 12. D and E). As expected, 012 did not an effect. Taken together, 
these results suggest guanidine compounds inhibit proliferation of Oli-neu cells.  
 
We also wanted to examine the potency of guanidine compounds with respect to their 
effect on proliferation of Oli-neu cells. For this purpose, Oli-neu cells were treated with 5 
guanidine derivatives at several concentrations for 2 days with addition of EDU during 
the last 5h of treatment (Figure 12. F). Treatment with none of the compounds resulted 
in a significant decrease in the percentage of PDGFRA+EDU+ cells at 1 µM. As 
expected, compound 002 was the most potent, causing a robust decrease in the 
percentage of PDGFRA+EDU+ cells at concentration as low as 10 µM. Although 
treatment with 005 and 008 at 10 µM also inhibited proliferation and Oli-neu cells, this 
effect was less robust. Contrary to that, 006 was effective only at 50 µM, while 012 did 
not inhibit proliferation at any concentrations tested (Figure 12. F). 
 
To determine whether decrease in cell proliferation is due to decreased expression of 
PDGFRA in general or increased internalization of PDGFRA from the surface of Oli-neu 
cells, we treated Oli-neu cells with guanidine compounds for 2 days at 50 µM and 
performed live staining for PDGFRA (Figure 13. A). We quantified the percentage of Oli-
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neu cells that express PDGFRA on their surface at high level among all DAPI+ cells 
(Figure 13. B). Cells that express PDGFRA at high level were distinguished from those 
that express PDGFRA at low level by qualitative assessment of the intensity of 
immunostaining. The amount of receptor present on the surface of these cells varied 
within the cell population, even under control conditions. The percentage of cells 
expressing PDGFRA at high level, among all PDGFRA+ cells followed the general trend 
observed with proliferation experiments. However, the differences did not reach 
significance under any conditions. These results suggest that upon 2-day treatment of 
Oli-neu cells with guanidine compounds, majority of cells still express PDGFRA. 
Therefore, change in receptor expression and/or internalization are not likely causing the 
observed decrease in Oli-neu cell proliferation. 
 
The decrease in cell density and proliferation of Oli-neu cells might be due to citotoxicity 
of guanidine compounds. In order to test this, we cultured Oli-neu cells in the presence 
of guanidine compounds for 16h. To detect cells that during this time underwent 
early/intermediate stages of apoptosis, we performed Annexin V staining in combination 
with propidium iodide (PI). Mitomycin C (MMC), an apoptotic inducer in variety of 
cancers, was used as positive control. The percentage of Annexin V+ cells was 
quantified by flow cytometry (Figure 14. A). Our results show that all guanidine 
compounds, as well as MMC, caused an increase in the percentage of Annexin V+ cells 
by at least 2 fold relative to control (Figure 14. B). We also examined proliferation of Oli-
neu cells treated with guanidine compounds during the same time frame. The 
percentage of EDU+ cells was quantified by flow cytometry (Figure 14. C). After 16h 
treatment with compounds 005, 006 and 008, the percentage of EDU+ Oli-neu cells 
decreased by approximately 2 fold relative to control. As expected, compound 002 was 
the most potent, causing a decrease in the percentage of EDU+ cells close to 8 fold 
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(Figure 14. D). Taken together, these results imply that guanidine compounds are at 
least partially toxic. However, the effect of compound 002 cannot be attributed solely to 
toxicity since the inhibition of proliferation is greater compared to toxicity. 
 
Guanidine compounds inhibit proliferation of dissociated primary mouse 
OPCs  
 
The next question we asked was whether the inhibition of proliferation by guanidine 
compounds is cell-type specific. Oli-neu cells were derived from primary mouse OPCs 
by retroviral transduction with mutated analog of c-neu proto-oncogene. T-neu oncogene 
differs from its analog by a point mutation, which causes t-neu to be constitutively active 
and results in indefinite proliferation capacity of cells that carry this oncogene. Due to 
different profile, OPCs might not necessarily respond in the same manner to guanidine 
compounds. 
 
We therefore wanted to examine whether change in OPC proliferation, as a response to 
treatment with guanidine compounds, would occur in the manner similar to that of Oli-
neu cells. To answer this question, dissociated primary mouse OPCs were treated with 
002, 005, 006, 008 and 012 at 50 μM for 1 day. Compounds were added to the cells 
together with 20 ng/ml mouse PDGFAA, a known survival factor and mitogen for OPCs, 
which is necessary for maintenance of progenitor phenotype in dissociated cultures. 
EDU was added during the last 5h of incubation when cells were fixed and stained for 
PDGFRA (Figure 15. A). Our results indicate that, although the response of OPCs 
followed a similar trend compared to that of Oli-neu cells, decrease in the percentage of 
proliferating cells was less robust (Figure 15. B). As expected, 002, 005 and 008 were 
the most potent, while 012 caused marginal decrease in the percentage of EDU+ cells. 
92	  
Treatment of OPCs with 006 resulted in a moderate decrease in proliferation that did not 
reach significance.  
 
OPCs are kept in dissociated culture in strictly defined medium and in an environment 
that differs to that in vivo. To provide conditions more similar to those in vivo, we used 
organotypic cortical cultures from NG2creBAC:ZEG double transgenic mice in which 
EGFP is expressed in OPCs and their progeny. To examine proliferation of mouse 
OPCs in slice cultures, we limited our treatments to compounds 002 and 006. These 2 
compounds are positional isomers that differ only in the position of methoxy residue. 
However, they exert different potency in terms of Pdgfra transcription and proliferation of 
Oli-neu cells and OPCs. Cortices from NG2creBAC:ZEG mice were dissected and 
incubated for 7-9 days. Compounds were added during the last 2 days of incubation 
while EDU was added during the last 5h of treatment. Treatment with compound 002 
resulted in a decrease in the percentage of EDU+ OPCs, which reached significance 
only in white matter and only at the higher concentration applied. Although compound 
006 also caused a decrease in the percentage of proliferating OPCs, this decrease was 
not significant (Figure 15. C and D). 
 
PDGF is the best known and most potent mitogen for OPCs. Addition of exogenous 
PDGF was shown to increase proliferation of OPCs in white matter, but not gray matter 
in organotypic slice cultures (Hill et al, 2013). We wanted to examine whether guanidine 
compounds would block the effect of exogenous PDGF. For this purpose, we added 
PDGF during the last 2 days of incubation to the final concentration of 50 ng/ml, as this 
was the amount that has been shown to cause a plateau in OPC proliferation in slice 
cultures. As expected, addition of PDGF resulted in an increase in proliferation in white 
matter, but not gray matter (Hill et al, 2013). However, when PDGF was applied together 
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with compounds 002 and 006, PDGF-induced proliferation was inhibited. Compound 002 
was more potent and caused significant reduction in the percentage of EDU+ cells in 
white matter even at low concentration of concentration of 1 µM, while treatment with 
compound 006 resulted in inhibition of PDGF-induced proliferation only at higher 
concentration of 10 µM. At 10 µM, compound 002 inhibited proliferation of gray matter 
OPCs as well (Figure 15. C and D). 
 
In our experiments with slice cultures, we also observed that OPCs were not the only 
cells which proliferation was inhibited by guanidine compounds. Other cell types, which 
we did not characterize, also incorporated EDU under control conditions and upon 
addition of exogenous PDGF. EDU incorporation was dramatically reduced upon 
treatment with guanidine compounds. This suggests that the effect our compounds exert 
is not specific for oligodendrocyte-lineage cells.  
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Figure 12. Changes in Oli-neu cell density and proliferation upon treatment 
w ith guanidine compounds. Oli-neu cells were treated with guanidine compounds for 
2 days at 50 µM with addition of EDU during the last 5h of treatment. We observed a 
striking difference in cell density (A). Oli-neu cells were fixed and stained for PDGFRA 
(B). EDU+PDGFRA+ cells among all PDGFRA+ cells were quantified (C).  Upon 2-day 
treatment of Oli-neu cells with guanidine compounds, RNA was extracted. qPCR results 
show an increase in the transcript levels of p21 and p27 (D and E). (F) Quantification of 
PDGFRA+EDU+ among all PDGFRA+ Oli-neu cells after treatment with guanidine 
compounds at different concentrations. * p < 0.05 relative to control, ** p < 0.01 relative 
to control, *** p < 0.001 relative to control, one-way ANOVA with Bonferroni posthoc 
analysis. Error bars are standard errors of the mean.	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Figure 13. Guanidine compounds do not cause decrease in PDGFRA 
expression or receptor internalization. Oli-neu cells were treated with guanidine 
compounds for 2 days at 50 µM when live staining for PDGFRA was performed (A). 
Quantification of the cells expressing PDGFRA at high level among all cells. Error bars 
are standard deviations of the mean, no statistical significance was found, one-way 
ANOVA with Bonferroni posthoc analysis.	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Figure 14. Decrease in Oli-neu cells density upon treatment w ith guanidine 
compounds can be partially attributed to citotoxicity. Oli-neu cells were treated 
with guanidine compounds for 16h when they were stained for Annexin V and PI. 
Annexin V+ and PI+ cells were counted using flow cytometry (A). The percentage of 
apoptotic cells, identified by Annexin V labeling, was quantified. All compounds caused 
an increase in the percentage of apoptotic cells by at least 2 fold (B). We also examined 
changes in proliferation in Oli-neu cells treated with guanidine compounds for 16h. Oli-
neu cells that incorporated EDU were counted using flow cytometry. Histograms are 
showing the number and percentage of EDU+ cells (C). Quantification (D) shows that 
compounds 005, 006 and 008 caused approximately 2-fold decrease, while treatment 
with 002 resulted in close to 8-fold decrease in the percentage of proliferating cells.	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Figure 15. Changes in primary mouse OPC proliferation after treatment w ith 
guanidine compounds. After 1-day treatment of primary mouse OPCs with guanidine 
derivatives at 50 μM, OPCs were stained for PDGFRA and EDU (A). (B) Quantification 
of the PDGFRA+ cells that incorporated EDU during the last 5h of treatment among all 
PDGFRA+ cells.  Compounds 002, 005 and 008 caused a significant decrease in the 
percentage of proliferating cells, 002 being the most potent. * p < 0.01 relative to control, 
** p < 0.001 relative to control, one-way ANOVA with Bonferroni post-hoc analysis. Error 
bars are standard errors of the mean. (C) Organotypic cortical slice cultures obtained 
from NG2creBAC:ZEG double transgenic mice were exposed to guanidine compounds 
for 2 days with and without addition of exogenous PDGF. EDU was added during the 
last 5h of treatment when slices were fixed and stained for EDU (red). (D) Quantification 
of the GFP+ cells that incorporated EDU during the last 5h of treatment among all GFP+ 
cells. + p < 0.001 relative to gray matter, # p < 0.001 relative to respective control, * p < 
0.001, two-way ANOVA with Bonferroni post-hoc analysis.	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Guanidine compounds do not inhibit proliferation of glioblastoma-derived cell 
lines, primary astrocytes and HEK cells 	  
 
To further address the question whether compounds-induced inhibition of proliferation is 
specific for PDGFRA-expressing cells, we tested the effects of guanidine compounds on 
several other cell types. All treatments were done as previously. Cells were treated with 
50 μM compounds for 2 days with the addition of EDU during the last 5h of treatment. 
Then, they were fixed and stained for EDU and the percentage of EDU+ cells among all 
cells, identified by DAPI, was quantified. 
 
Astrocytes and HEK 293 cells do not express PDGFRA. Therefore, we hypothesized 
that guanidine compounds would not inhibit proliferation of these two cell types. As 
expected, treatment with none of the compounds resulted in a decrease in the 
percentage of EDU+ cells (Figure 16. A). 
 
Glioblastoma-derived cell lines A172, U251 and T98G differ in transcript levels of 
PDGFRA and PDGFRB. Compared to the remaining two cell lines, U251 has the highest 
level of PDGFRA, while A172 has the highest level of PDGFRB transcript. T98G has 
moderate levels of both PDGFRA and PDGFRB. Therefore, U251 most closely 
resembles OPCs (Lokker et al, 2002). We hypothesized that, upon treatment with 
guanidine compounds, U251 would show the most robust decrease in the percentage of 
EDU+ cells, T98G would show modest decrease, while A172 would have little or no 
response. Quantification of the percentage of EDU+ cells showed that all 3 glioblastoma-
derived cell lines respond in a manner that resembles that of Oli-neu cells. However, 
contrary to that of Oli-neu cells, the observed decrease in proliferation was modest for all 
cell lines. None of the compounds significantly reduced proliferation of U251 and T98G. 
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Unexpectedly, compounds 002 and 005 caused a significant decrease in the 
proliferation of A172. However, the decrease in proliferation was less robust compared 
to the one observed with Oli-neu cells or primary mouse OPCs (Figure 16. B). We also 
wanted to examine whether guanidine compounds would alter PDGFRA transcription in 
glioblastoma-derived cell lines. Our qPCR results showed that the change in PDGFRA 
or PDGFRB transcript levels upon treatment with guanidine compounds was marginal 
and it did not reach 2 fold (Figure 16. C). 
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Figure 16. Guanidine compounds inhibit proliferation of A172, but do not inhibit 
proliferation of U251, T98G, HEK 293 cells and primary mouse astrocytes. Cells 
were treated with guanidine compounds for 2 days when the percentage of EDU+ cells 
among all cells was assessed. Bar graphs show quantification of cells that incorporated 
EDU during the last 5h of treatment. Primary mouse astrocytes and HEK 293 cells did 
not show a change in proliferation (A). The three glioblastoma-derived cell lines showed 
proliferation changes similar to those of Oli-neu cells and OPCs. However, the decrease 
in proliferation was not significant in any circumstances, except when cell line A172 was 
treated with compounds 002 and 005 (B). * p < 0.05 compared to control, ** p < 0.01 
compared to control, one way ANOVA with Bonferroni post hoc analysis. (C) We 
analyzed the changes in Pdgfra and Pdgfrb transcript levels after glioblastoma-derived 
cell lines had been treated with guanidine compounds for 2 days. Changes in 
transcription in all three cell lines were marginal and less than 2-fold under all conditions 
examined. dCtC = delta Ct of DMSO control; dCtT = delta Ct upon treatment with 
compounds.	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Discussion	  
 
Since signaling through PDGFRA is critical for OPC proliferation, we hypothesized that 
downregulation of Pdgfra transcription would inhibit proliferation of PDGFRA-expressing 
cells. As expected, the percentage of proliferating Oli-neu cells and primary mouse 
OPCs was robustly reduced upon treatment with guanidine compounds. Decrease in cell 
proliferation might be due to toxicity since treatment with guanidine compounds resulted 
in an increase in the percentage of apoptotic Oli-neu cells by approximately 2 fold. This 
might be the case for compounds 005 and 008 where decrease in proliferation under the 
same conditions was also 2 fold. However, decrease in proliferation cannot be attributed 
solely to toxicity for compound 002. Although 16h treatment with 002 resulted in 2.1-fold 
increase in the percentage of apoptotic cells, decrease in proliferation observed under 
the same conditions was 7.7 fold.  
 
Decrease in OPC proliferation is also evident in organotypic slice cultures. Only high 
dose of more potent compound 002 was able to inhibit proliferation under basal 
conditions. However, when compounds were added together with PDGF, they inhibited 
PDGF-induced proliferation of OPCs. Low dose of compound 002 and high dose of 
compound 006 were required for this effect. Upon 2-day treatment of Oli-neu cells, 
PDGFRA protein was shown to be present on the cell surface. We did not examine the 
expression of PDGFRA on the surface of OPCs in the slice culture. However, since slice 
cultures were treated with compounds for 2 days, it is possible that primary OPCs 
showed continues expression of PDGFRA at this time as well. This suggests that 
PDGFRA is not the primary target for guandince compounds. This is further supported 
by our observation that proliferation of GFP- cells, which are unlikely of oligodendrocyte 
lineage, was also inhibited by guanidine compounds.  
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Both Oli-neu cells and OPCs express PDGFRA, while HEK 293 cells and astrocytes do 
not, so it is possible that PDGFRA downregulation is at least in part responsible for the 
observed decrease in proliferation. This appears to contradict the result obtained from a 
similar experiment that utilized glioblastoma-derived cell lines. However, we need to 
keep in mind that glioblastoma-derived cell lines used in our study might not necessarily 
be derived from oligodendrocyte lineage cells. It is possible that they express other 
growth factor receptors and that signaling through these pathways overrides the effect of 
compounds. Another possibility is that target molecule for compounds that regulates 
Pdgfra transcription is not expressed by glioblastoma-derived cell lines. This is 
supported by the fact that treatment with guanidine compounds did not result in a 
decrease in PDGFRA mRNA level in glioblastoma-derived cell lines.  
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Chapter 6 – Summary, discussion and conclusions 	  
 
Summary 
 
OPCs are the major source of oligodendrocytes during embryonic development and 
adulthood, but also in pathological conditions. Since OPCs are the largest pool of cycling 
cells that are readily available for recruitment upon myelin injury, they represent an 
attractive target for therapies for demyelinating disorders. Signaling through PDGFRA is 
the key mechanism that regulates OPC proliferation and their differentiation into mature 
oligodendrocytes. Aberrant PDGFRA expression has been implied in the occurrence of 
CNS malignancies and inhibition of PDGFRA signaling could be a valuable addition to 
the current treatments of certain CNS cancers. Small molecules are putative candidates 
for the therapeutic interventions because they can be designed to be highly specific for 
their targets to be able to cross blood brain barrier. Identification of such compounds 
might provide a novel direction in the drug design for nervous system disorders. Since 
PDGFRA is critical for regulation of OPC proliferation and differentiation, identification of 
compounds that target regulators of its expression and/or signaling could provide a 
significant contribution to treatments of demyelinating disorders and CNS malignancies.  
 
The purpose of this study was to identify small molecule compounds that downregulate 
Pdgfra transcription in OPCs. We hypothesized that the inhibition of transcription of this 
particular receptor would result in inhibition of OPC proliferation and stimulation of their 
differentiation into mature oligodendrocytes. 
 
In the primary screen, we indeed identified 7 compounds that downregulated PDGFRA-
luc activity in a dose-response manner. Guanidine compounds (39D11, 40A10, 40B10 
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and 39E11) also downregulated endogenous Pdgfra transcription, assessed by qPCR, 
while structurally non-related compound 42E8 did not. Downregulation of transcription 
was specific for Pdgfra and not for other RTKs expressed by OPCs. Guanidine 
compounds also inhibited proliferation of Oli-neu cells and primary mouse OPCs, 
assessed by EDU labeling, but did not inhibit proliferation of primary mouse astrocytes, 
HEK 293 cells and glioblastoma-derived cell lines. They did not, however, promote 
differentiation of primary rat OPCs into mature oligodendrocytes. 
 
Discussion 
 
Luciferase assay is a powerful tool widely used for high-throughput screening purposes. 
However, studies using luciferase assay are most commonly done on stably transfected 
cell lines where firefly luciferase is driven by gene’s endogenous regulatory sequences. 
Using only a portion of Pdgfra gene to drive reporter expression was a disadvantage in 
our primary screen, which could be overridden by stable transfection of Oli-neu cells. 
 
To identify compounds that promote differentiation, a valuable addition to the technique 
would be to use a second plasmid for the primary screen, which contains regulatory 
elements of an early oligodendrocyte gene driving reporter transcription. Cnp would be a 
good choice for this purpose, since it gets upregulated when Oli-neu cells are treated 
with differentiation inducers (Joubert et al, 2010). Differential regulation of OPC-specific 
and early oligodnedrocyte gene in differentiating Oli-neu cells would prevent selection of 
false positives.  
Oli-neu cells are immortalized cell line and, in our hands, they were less responsive to 
differentiation inducers than primary OPCs. At the time when screening was preformed, 
we could not obtain sufficient numbers of viable OPCs and therefore chose to use Oli-
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neu cells instead. Using primary OPCs from one of the numerous transgenic mouse 
lines available that have florescent reporter driven by regulatory sequences of OPC- and 
oligodendrocyte-specific genes might provide better biological system to detect 
differentiating OPCs.  
 
SAR analysis of guanidine compounds revealed residues that are responsible for 
compounds’	  potency. Two structural modifications that resulted in the highest potency of 
guanidine compounds are: presence of methoxy group at carbon 2 of the benzyl ring 
and elongation of the carbon chain linking guanidine group and benzyl ring. Such 
modifications might exert their effect by increasing compound lipophylicity, stabilizing 
compound-target interaction or facilitating the interaction between the pharmacophore 
and the receptor. A combination of these and other modifications might further improve 
compound potency (Figure 9). Once the top candidates are ready to be tested for their 
biological effect in vivo, replacement of hydrogen atoms with fluorine might be a valuable 
modification. Presence of fluorine may extend compound’s half-life without affecting the 
biological activity if such replacement is done at the site of metabolic oxidation.  
 
We did not perform thorough analysis of a relationship between compound structure and 
toxicity. Although our top candidate’s biological effect greatly surpasses its toxicity, 
guanidine compounds were found to be at least partially cytotoxic for Oli-neu cells 
(Figure 14). Further analysis needs to be conducted to identify residues that are 
responsible for compounds’	   toxicity and which structural modifications can be made to 
decrease it. 
 
111	  
Guanidine compounds dramatically inhibited Pdgfra transcription and proliferation of Oli-
neu cells. They did not, however, promote their differentiation into oligodendrocytes. 
Together with the data obtained from experiments performed on primary OPCs, these 
results suggest that downregulation of Pdgfra transcription and inhibition of proliferation 
is not sufficient for OPC differentiation to occur under the conditions we used. This is 
consistent with studies that suggest cell cycle withdrawal is necessary, but not sufficient 
to induce OPC maturation and that control of oligodendrocyte differentiation involves 
other factors that operate between cell cycle exit and differentiation (Casaccia-Bonefil et 
al, 1999). Identification of compounds that target such factors will contribute in 
succeeding in our goal to use small molecule compounds as additional therapy for 
demyelinating disorders.  
 
Together with the correlation between downregulation of Pdgfra transcription and 
inhibition of Oli-neu cell proliferation, lack of compounds’	  effect on astrocytes and HEK 
293 cells, which do not express PDGFRA, implies that Pdgfra is a direct/indirect target of 
guanidine compounds. This is further supported by the fact that neither PDGFRA 
transcription nor proliferation of two glioblastoma-derived cell lines was inhibited by 
guanidine compounds. However, since compounds 002 and 005 inhibited proliferation of 
A172 but did not downregulate transcription of PDGFRA or PDGFRB in these cells, this 
leads to speculation that PDGF receptors are not the only targets for guanidine 
compounds. This is consistent with the biological effect of compound 006, which did not 
alter Pdgfra transcription, but did inhibit proliferation of Oli-neu cells. Future research, 
aimed toward identifying direct target/s of guanidine compounds, will contribute to the 
growing knowledge of PDGFRA regulation and its role in OPC differentiation.  
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It was encouraging to discover that the effect of guanidine compounds is somewhat cell-
type specific, since proliferation of Oli-neu cells and primary OPCs was inhibited by 
guanidine compounds, but that of astrocytes and HEK 293 cells was not. However, we 
also observed a decrease in the percentage of EDU+ cells that were not GFP+ in our 
slice culture system, which implies guanidine compounds act on a broader spectrum of 
cell types. Although proliferation of glioblastoma-derived cell lines was not efficiently 
inhibited, this does not necessarily mean that cells derived from other types of cancers 
would respond similarly to the three cell lines examined. It would be interesting to find 
out whether cells obtained from biopsies of patients with gliomas would be more 
responsive. In addition, characterization of cell types that these compounds are specific 
for might provide us with a direction toward other types of cancers that can be potentially 
treatable.  
 
To this date, the effect that N-methyl-N-benzyl guanidine or its derivatives have on 
proliferation of varios cell types has never been examined. In fact, to my best 
knowledge, none of the guanidine compounds identified in this study, have been 
examined in other types of bioassays. However, several other guanidine derviatvies 
have been tested in 2 other studies. These compounds were not, however, derivatives of 
our lead compound, N-methyl-N-benzyl guanidine, but of another lead, N-benzyl 
guanidine, which does not have methyl group on the nitrogen athom of the guanidine. 
Four compounds were candidates in the high throughput screening study related to 
obesity and diabetes, aimed towards identifying small molecule compounds that would 
alieveiate these disorders. These compounds were: N-(2-chloro-benzyl)guanidine, N-(2-
methoxy-benzyl)guanidine, N-(3-methoxy-benzyl)guanidine and N-(4-methoxy-
benzyl)guanidine. They were identified as top candidates from the screening. However, 
eventually, they were shown to be inactive. In a separate study, aimed towards 
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identifying inhibitors for substrates of cytochrome p450 in a high throughput screen, a 
different derivative of N-benzyl guanidine, N-(3-iodo-benzyl)guanidine, was identified 
and shown to be active. This compound has iodine as a substituent on the benzyl ring. 
Results of these studies are encouraging as they support our conclusions that presence 
of chlorine and methoxy groub on C2 and C3 of the benzyl ring might be an important 
modification. In addition, we should also consider using iodine as substituent as well. 	  
Aberrant PDGF and PDGFR expression has been detected in various types of 
malignancies, including those occurring in the CNS (Hermanson et al, 1992; Di Rocco et 
al, 1998; Martinho et al, 2009; Ozawa et al, 2010; Heldin, 2013). PDGFRA is the second 
most frequently mutated RTK gene in glioblastoma (The Cancer Genome Atlas 
Research Network, 2008). Amplification is the most commonly observed PDGFRA gene 
alteration, while point mutations, deletions and gene rearrangements are rare and occur 
more frequently in glioma samples that already have PDGFRA amplification (Martinho et 
al, 2009; Verhaak et al, 2010; Ozawa et al, 2010). 
 
Awareness of the PDGF signaling contribution to cancer growth has led to development 
of different types of inhibitors that are now under preclinical and clinical evaluation 
(Pietras et al, 2003; Heldin, 2013). Antibodies and soluble extracellular parts of the 
receptors can intervene with PDGF signaling by binding to PDGFs or PDGFRs, prevent 
their interaction or promote their degradation (Hawthorne et al, 2008; Shen et al, 2009). 
Although reasonably specific, these types of inhibitors are expensive and difficult to 
administer. Using small molecule compounds for cancer therapy has numerous 
advantages –	   they are potent, less expensive and easier to administer. Numerous 
studies have explored the effects of developing compounds and several compounds 
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were shown to be very promising in cancer treatment. However, none of these 
compounds is specific and they were all shown to inhibit other kinases (Morris and 
Abrey, 2010; Paulsson et al, 2011; Heldin, 2013). Imatinib is one of the first and most 
promising candidates used in the treatment of multiple cancers, such as chronic 
myelogenous leukemia and gastrointestinal stromal tumors (Iqbal and Iqbal, 2014). 
However, in addition to PDGFRA, imatinib inhibits two other RTKs, Abl and Kit, as well 
as serine/threonine kinase Raf (Heldin, 2013). The lack of specificity of imatinib and 
other small molecule compounds contributes to their side effects. In addition, imatinib 
was shown to have mild potency in clinical trials in glioma patients (Reymond et al, 
2008), which might be attributable to its poor penetration through the blood brain barrier 
(Takayama et al, 2002; Senior, 2003).  
 
In addition to the lack of imatinib’s specificity, its action, as well as that of other 
compounds, is directed towards inhibiting PDGFRA kinase activity and has not been 
successful in treatments of gliomas. Targeting PDGFRA activity in its core, through 
regulation of its transcription, might prove to be more effective. Guanidine compounds 
discovered in our study were shown to be specific for Pdgfra transcription and not that of 
other tested RTKs, Fgfr1 and Fgfr3, and therefore represent promising candidates for 
future cancer therapies. In addition, their lower molecular weight might contribute to 
easier delivery to the CNS. Future research needs to be conducted to assess guanidine 
compounds’	  transportation and metabolism. 
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Concluding remarks 
 
Glial cell dysfunctions are involved in the occurrence and development of many nervous 
system disorders. The dynamic of the disease progress is such that it often prevents the 
development of the diagnostic and therapeutic strategies applicable at each time point 
and in every location. One of the most important initiatives in the therapy today is 
development of treatments that are personalized and tailored to the biology and stage of 
the disease in the individual patients. Small molecules are putative candidates for 
therapeutic interventions in the brain because they can be designed to be highly 
selective, are able to cross blood brain barrier and can be conveniently modified to 
adjust to different conditions, such as different patients or pathological processes. 
Identification of such molecules may provide a novel direction in the drug design for 
devastating nervous system disorders, which can complement current treatments. 
PDGFRA signaling pathway is an attractive target for small molecules. Pdgfra 
transcription and proliferation of PDGFRA-expressing cells were found to be inhibited by 
compounds discovered in our study. How specific these compounds are and whether 
they can be used to inhibit PDGFRA signaling in vivo remains to be established.  
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